<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PeerJ</journal-id><journal-id journal-id-type="iso-abbrev">PeerJ</journal-id><journal-id journal-id-type="pmc-domain-id">2057</journal-id><journal-id journal-id-type="pmc-domain">peerj</journal-id><journal-id journal-id-type="publisher-id">peerj</journal-id><journal-title-group><journal-title>PeerJ</journal-title></journal-title-group><issn pub-type="epub">2167-8359</issn><publisher><publisher-name>PeerJ, Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12767491</article-id><article-id pub-id-type="pmcid-ver">PMC12767491.1</article-id><article-id pub-id-type="pmcaid">12767491</article-id><article-id pub-id-type="pmcaiid">12767491</article-id><article-id pub-id-type="pmid">41497268</article-id><article-id pub-id-type="doi">10.7717/peerj.20478</article-id><article-id pub-id-type="publisher-id">20478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Biochemistry</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Ophthalmology</subject></subj-group><subj-group subj-group-type="heading"><subject>Metabolic Sciences</subject></subj-group></article-categories><title-group><article-title>Research progress on glycolytic reprogramming in ophthalmic diseases</article-title></title-group><contrib-group><contrib id="author-1" contrib-type="author"><name name-style="western"><surname>Gong</surname><given-names initials="X">Xiaoqi</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-2" contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="J">Jiaojiao</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-3" contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="Y">Yibo</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-4" contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="G">Guodong</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib id="author-5" contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="Y">Yixue</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib id="author-6" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jing</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-7" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuxi</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-8" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jun</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-9" contrib-type="author" corresp="yes"><name name-style="western"><surname>Song</surname><given-names initials="J">Jike</given-names></name><email>edusjk@163.com</email><xref rid="aff-1" ref-type="aff">1</xref><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib id="author-10" contrib-type="author" corresp="yes"><name name-style="western"><surname>Bi</surname><given-names initials="H">Hongsheng</given-names></name><email>hongshengbi1@163.com</email><xref rid="aff-2" ref-type="aff">2</xref><xref rid="aff-3" ref-type="aff">3</xref></contrib><aff id="aff-1"><label>1</label><institution>Shandong University of Traditional Chinese Medicine</institution>, <city>Jinan</city>, <state>Shandong</state>, <country>China</country></aff><aff id="aff-2"><label>2</label><institution>Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine</institution>, <city>Jinan</city>, <state>Shandong</state>, <country>China</country></aff><aff id="aff-3"><label>3</label><institution>Shandong Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases</institution>, <city>Jinan</city>, <state>Shandong</state>, <country>China</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Oliveira</surname><given-names initials="S">Sonia</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>2</day><month>1</month><year iso-8601-date="2026">2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">504017</issue-id><elocation-id>e20478</elocation-id><history><date date-type="received" iso-8601-date="2025-04-11"><day>11</day><month>4</month><year iso-8601-date="2025">2025</year></date><date date-type="accepted" iso-8601-date="2025-11-05"><day>5</day><month>11</month><year iso-8601-date="2025">2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>06</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-07 09:25:13.140"><day>07</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169;2026 Gong et al.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Gong et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution License</ext-link>, which permits using, remixing, and building upon the work non-commercially, as long as it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="peerj-14-20478.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://peerj.com/articles/20478"/><abstract><p>The retina is one of the most energy-demanding tissues in the human body. Retinal energy metabolism is primarily dominated by aerobic glycolysis, with more than 80% of the glucose consumed being converted to lactic acid. As a highly energy-consuming tissue, the metabolic characteristics of the retina, especially aerobic glycolysis, are essential for maintaining retinal cell function during normal physiological processes. However, in disease states, this metabolic balance is disrupted, leading to a range of pathological changes. There is currently growing evidence that metabolic reprogramming is a pathological cause of diseases such as retinal degeneration, uveal melanoma, and glaucoma. This article reviews the mechanisms involved in metabolic reprogramming in ocular diseases and describes relevant therapeutic targets. Despite the many advances, the regulatory mechanisms of metabolic reprogramming in ophthalmic diseases still need to be thoroughly investigated, and new therapeutic strategies are expected to be developed based on this in the future.</p></abstract><kwd-group kwd-group-type="author"><kwd>Metabolic reprogramming</kwd><kwd>Aerobic glycolysis</kwd><kwd>Retinal degeneration</kwd><kwd>Age-related macular degeneration</kwd><kwd>Retinitis pigmentosa</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>The Shandong Provincial Key Research and Development Programme</funding-source><award-id>2021LCZX09</award-id></award-group><award-group id="fund-2"><funding-source>The Shandong Provincial Natural Science Foundation</funding-source><award-id>ZR2021LZY045</award-id></award-group><award-group id="fund-3"><funding-source> The Shandong Provincial Medico-Health Science and Technology Project</funding-source><award-id>202307021729</award-id></award-group><award-group id="fund-4"><funding-source>The Shandong Provincial Traditional Chinese Medicine Science and Technology Project</funding-source><award-id>Q-2023015</award-id></award-group><funding-statement>This study was supported by the Shandong Provincial Key Research and Development Programme (2021LCZX09), the Shandong Provincial Natural Science Foundation (ZR2021LZY045), the Shandong Provincial Medico-Health Science and Technology Project (202307021729), and the Shandong Provincial Traditional Chinese Medicine Science and Technology Project (NO. Q-2023015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Under normal aerobic conditions, intracellular pyruvate enters the mitochondria and participates in the tricarboxylic acid cycle (TCA), generating adenosine triphosphate (ATP) through oxidative phosphorylation. Under low or no aerobic conditions, pyruvate is directly reduced to lactate through glycolysis to generate energy (<xref rid="ref-62" ref-type="bibr">Rabinowitz &amp; Enerb&#228;ck, 2020</xref>). In 1921, German scientist Otto Warburg&#160;made a groundbreaking discovery:&#160;even under sufficient oxygen, cancer cells preferentially utilize glycolysis to obtain most of their energy. This type of glycolysis under aerobic conditions is called the &#8220;Warburg effect&#8221;, also known as metabolic reprogramming (<xref rid="ref-78" ref-type="bibr">Warburg, 1956</xref>). Notably, metabolic reprogramming is a hallmark of malignancy first recognized a century ago&#160;and has since become a focal point in cancer research. In some cases, reprogrammed metabolic activities can be exploited to diagnose, monitor, and treat cancer. Consequently,&#160;several metabolic inhibitors designed to target&#160;key&#160;pathways of metabolic activity have entered clinical trials (<xref rid="ref-28" ref-type="bibr">Hu et al., 2024</xref>).</p><p>The retina&#160;is unique as the only non-proliferative tissue capable of sustained aerobic glycolysis (<xref rid="ref-82" ref-type="bibr">Wubben et al., 2017</xref>). Recent studies&#160;reveal&#160;that many ophthalmic diseases are linked to metabolic reprogramming,&#160;suggesting that&#160;related pathway proteins&#160;could serve as&#160;therapeutic targets. This article&#160;reviews&#160;recent advances, explores the role of metabolic reprogramming in ophthalmic diseases, and&#160;lays the groundwork&#160;for developing new strategies to&#160;target metabolic pathways therapeutically.</p></sec><sec><title>Survey Methodology</title><p>This review is primarily aimed at:</p><list list-type="simple" id="list-1"><list-item><label> 1.</label><p>Ophthalmology researchers: to provide new perspectives on metabolic regulation in disease mechanisms.</p></list-item><list-item><label> 2.</label><p>Clinicians: to analyse advances in translational medicine such as stem cell therapy and gene editing.</p></list-item><list-item><label> 3.</label><p>Molecular biologists: to explore the molecular pathways of epigenetic-metabolic interactions.</p></list-item><list-item><label> 4.</label><p>Drug developers: Evaluate the therapeutic potential of targeting metabolic enzymes or reprogramming technologies.</p></list-item></list><p>Literature Search Strategies</p><list list-type="simple" id="list-2"><list-item><label> 1.</label><p>Databases and Search Engines </p><list list-type="simple" id="list-3"><list-item><label> &#8226;</label><p><bold>International databases</bold>: PubMed, Web of Science, ScienceDirect, Cell Press, Nature Portfolio.</p></list-item><list-item><label> &#8226;</label><p><bold>Chinese databases</bold>: China Knowledge Network (CNKI) (<xref rid="fig-1" ref-type="fig">Fig. 1</xref>).</p></list-item></list></list-item><list-item><label> 2</label><p>Search Keywords</p><p>Core subject terms Combined search formula (example)</p><list list-type="simple" id="list-4"><list-item><label> &#8226;</label><p><bold>Metabolic reprogramming</bold>: metabolic reprogramming, metabolic remodeling, Warburg effect, glycolysis.</p></list-item><list-item><label> &#8226;</label><p><bold>Ocular Diseases</bold>: ocular diseases, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, retinal degeneration, macular degeneration, glaucoma, retinitis pigmentosa.</p></list-item><list-item><label> &#8226;</label><p><bold>Techniques/mechanisms</bold>: epigenetic regulation, stem cell therapy, gene therapy, cell reprogramming, epigenetic modifications, oxidative stress.</p></list-item></list><p>(metabolic reprogramming OR metabolic remodeling) AND (ocular diseases OR AMD OR glaucoma)</p></list-item><list-item><label> 3.</label><p>Time Frame</p><p>From January 2015 to March 2025, with priority given to the inclusion of high&#8212;impact studies from the last 5&#160;years (post&#8212;2020), <italic toggle="yes">e.g.</italic>,&#160;Nature, Cell series of journals, Science Translational Medicine, <italic toggle="yes">etc.</italic></p></list-item><list-item><label> 4.</label><p>Inclusion and exclusion criteria</p><p>Inclusion Criteria </p><list list-type="simple" id="list-5"><list-item><label> &#8226;</label><p><bold>Study type</bold>: basic research (<italic toggle="yes">e.g.</italic>,&#160;animal models, cellular experiments), preclinical trials, clinical trials, reviews and Meta-analyses.</p></list-item><list-item><label> &#8226;</label><p><bold>Relevance</bold>: Explicitly explore the mechanism of action or therapeutic application of metabolic reprogramming in ophthalmic diseases, <italic toggle="yes">e.g.</italic>,&#160;the association of metabolic pathways such as enhanced glycolysis with retinopathy. Application of reprogramming techniques (<italic toggle="yes">e.g.</italic>,&#160;cellular reprogramming, epigenetic interventions) in vision restoration.</p></list-item><list-item><label> &#8226;</label><p><bold>Language</bold>: English and Chinese literature.</p></list-item></list><p>Exclusion criteria </p><list list-type="simple" id="list-6"><list-item><label> &#8226;</label><p>Not related to ophthalmic diseases (<italic toggle="yes">e.g.</italic>,&#160;only discussing cancer metabolism).</p></list-item><list-item><label> &#8226;</label><p>Purely clinical observational studies that do not address metabolic mechanisms or therapeutic strategies.</p></list-item><list-item><label> &#8226;</label><p>Low-quality evidence: preprints that have not been peer-reviewed (unless the content is groundbreaking), replicated studies, or case reports with too small a sample size.</p></list-item></list></list-item></list><sec><title>Metabolic reprogramming</title><p>The Warburg effect is described as a reprogramming of cancer cell metabolism,&#160;whereby&#160;cells utilize more glucose than normal cells and redirect it toward anabolic processes such as lipid, RNA/DNA synthesis, and nicotinamide adenine dinucleotide phosphate (NADPH) generation,&#160;leading to&#160;incomplete glucose oxidation despite oxygen availability (<xref rid="ref-78" ref-type="bibr">Warburg, 1956</xref>). Intriguingly,&#160;Warburg noted that the retina was the only non-proliferative tissue capable of aerobic glycolysis,&#160;and subsequent studies revealed that this phenomenon is localized specifically to photoreceptors.&#160;Photoreceptors must continually regenerate their outer segment (OS) membranes,&#160;a process that demands not only catabolic energy production but also anabolic synthesis of lipids, proteins, and nucleic acids (<xref rid="ref-84" ref-type="bibr">Xu, Zhao &amp; Kang, 2024</xref>). Glucose is transported from the choroidal vasculature to photoreceptors (PRs) <italic toggle="yes">via</italic> the retinal pigment epithelium (RPE). Whereas&#160;RPE cells rely primarily on oxidative phosphorylation.&#160;In contrast,&#160;photoreceptor cells are more dependent on glycolysis.&#160;During aerobic glycolysis in photoreceptors,&#160;glucose is converted to lactate, which is transported to RPE cells.&#160;There,&#160;lactate is converted to pyruvate <italic toggle="yes">via</italic> lactate dehydrogenase (LDH), fueling mitochondrial oxidative phosphorylation (<xref rid="ref-33" ref-type="bibr">Kanow et al., 2017</xref>) (<xref rid="fig-2" ref-type="fig">Fig. 2</xref>). Notably, Rods shuttle glucose into the pentose phosphate pathway (PPP) to synthesize new membranes and facilitate OS generation (<xref rid="ref-88" ref-type="bibr">Zhang et al., 2016</xref>). Critically, Photoreceptor cell death is the ultimate cause of vision loss in many retinal disorders (<xref rid="ref-88" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="ref-14" ref-type="bibr">Fisher &amp; Ferrington, 2018</xref>). Thus, disruption of this metabolic balance between the outer retina and the retinal pigment epithelium can lead to photoreceptor outer segment dysplasia or even photoreceptor death, ultimately causing visual impairment. Remarkably, in many retinal diseases, the balance between the RPE and photoreceptor cells is disrupted. As a result, the RPE increases its dependence on glycolysis for energy production, using more of the available glucose to meet its own metabolic needs. This metabolic shift makes less glucose available to photoreceptors, whose ability to regenerate the outer segments is compromised due to insufficient energy and other biosynthetic raw materials (<xref rid="fig-2" ref-type="fig">Fig. 2</xref>). Hexokinase 2 (HK2), pyruvate kinase muscle isoform 2 (PKM2), and lactate dehydrogenase A (LDHA) are central isoforms regulating aerobic glycolysis and lactate production in PRs. Among these, HK2, the first key glycolytic enzyme, is predominantly expressed in PRs. Studies demonstrate that optic rod cell-specific deletion of <italic toggle="yes">Hk2</italic> reduces aerobic glycolysis and increases oxidative phosphorylation (OXPHOS) (<xref rid="ref-59" ref-type="bibr">Petit et al., 2018</xref>). Pyruvate kinase (PK), the final glycolytic enzyme, converts phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP) to pyruvate and ATP. Meanwhile, LDHA catalyzes the conversion of pyruvate to lactate in the last step of aerobic glycolysis. Strikingly, <italic toggle="yes">in vivo</italic> electroporation of LDHA or PKM2 expression reduces OS length (<xref rid="ref-7" ref-type="bibr">Chinchore et al., 2017</xref>). Furthermore, similar to HK2 and PKM2, LDHA is preferentially expressed in PRs, consistent with the spatial organization of aerobic glycolysis in the retina (<xref rid="ref-5" ref-type="bibr">Casson et al., 2016</xref>; <xref rid="ref-79" ref-type="bibr">Weh et al., 2020</xref>). These enzymes represent critical targets for metabolic reprogramming and its role in disease. Collectively, these findings suggest that targeting these enzymes may offer novel therapeutic strategies to reprogram metabolism and halt disease progression.</p><fig position="float" id="fig-1" orientation="portrait"><object-id pub-id-type="doi">10.7717/peerj.20478/fig-1</object-id><label>Figure 1</label><caption><title>PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources.</title><p>Academic literature indexed in PubMed, Web of Science, ScienceDirect, and China National Knowledge Infrastructure (CNKI) was retrieved.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="peerj-14-20478-g001.jpg"/></fig><fig position="float" id="fig-2" orientation="portrait"><object-id pub-id-type="doi">10.7717/peerj.20478/fig-2</object-id><label>Figure 2</label><caption><title>Schematic diagram of glucose metabolism of the RPE and photoreceptors in the RPE-retinal ecosystem.</title><p>Normal Vision: Under normal physiological conditions, normal glucose metabolism of the RPE and photoreceptors in the RPE-retinal ecosystem leads to normal vision; Vsion Dysfunction: Metabolic dysfunc-tion of the RPE and photoreceptors in the RPE-retinal ecosystem. Abbreviations: GLU, glucose; RPE, retinal pigment epithelium; PR, photoreceptor; TCA, tricarboxylic acid cycle; G-6-P, glu-cose-6-phosphate; PEP, phosphoenolpyruvate; HK2, hexokinase2; PKM2, pyruvate kinase mus-cle isoform 2; LDHA, lactate dehydrogenase A. Figure support was provided by figdraw.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="peerj-14-20478-g002.jpg"/></fig></sec><sec><title>Retinal degeneration</title><sec><title>Age-related macular degeneration</title><p>Age-related macular degeneration (AMD) is a progressive retinal disease that is the leading cause of vision impairment. It accounts for approximately 6% to 9% of global legal blindness, especially in people over 50 years of age (<xref rid="ref-15" ref-type="bibr">Fleckenstein, Schmitz-Valckenberg &amp; Chakravarthy, 2024</xref>). The pathogenesis of AMD is complex and involves multiple factors such as genetics, environment, and metabolism. Dysfunction and degeneration of RPE cells are considered to be the core pathogenesis of AMD. The advanced stages of AMD are categorized as atrophic (dry) and exudative (wet) (<xref rid="ref-19" ref-type="bibr">Guymer &amp; Campbell, 2023</xref>). Dry AMD is characterized by progressive RPE atrophy, leading to degeneration of photoreceptor cells and causing central vision loss. In wet AMD, abnormal proliferation of choroidal neovascularization (CNV) crosses the retina, leading to hemorrhage, leakage, and scar formation, further impairing visual function (<xref rid="ref-11" ref-type="bibr">Fabre et al., 2022</xref>).</p><p>A key feature of dry AMD is the loss of RPE and photoreceptors. <xref rid="ref-14" ref-type="bibr">Fisher &amp; Ferrington (2018)</xref> analyzed human donor tissues and demonstrated that mitochondrial damage in the RPE acts as a key driver of dry AMD pathology. Using diverse experimental approaches, their work revealed that RPE primary cultures from AMD donors exhibited disrupted mitochondrial structure, reduced mitochondrial number and mass, altered mitochondrial protein expression, and increased mitochondrial DNA damage&#8212;all correlating with disease severity (<xref rid="ref-14" ref-type="bibr">Fisher &amp; Ferrington, 2018</xref>). Critically, prior studies indicate that RPE cells predominantly rely on oxidative phosphorylation to meet energy demands (<xref rid="ref-33" ref-type="bibr">Kanow et al., 2017</xref>). However, research by <xref rid="ref-16" ref-type="bibr">Golestaneh et al. (2017)</xref> showed that RPE cells in AMD patients rely on glycolysis as the main source of ATP rather than oxidative phosphorylation.</p><p>When mitochondrial dysfunction occurs, these cells shift to aerobic glycolysis to sustain energy production. This metabolic adaptation reduces the availability of glucose for photoreceptors, which themselves depend on glycolysis for survival. Notably, rod photoreceptors secrete a cone survival factor that enhances glucose uptake by cone cells, establishing a metabolic interdependence between rods and cones. Consequently, rod degeneration precedes cone loss (<xref rid="ref-9" ref-type="bibr">Curcio, Medeiros &amp; Millican, 1996</xref>). Given the macula&#8217;s high density of metabolically demanding cone photoreceptors, it is likely that RPE and photoreceptor death occurs preferentially in this region, explaining why macular degeneration is a hallmark of advanced AMD.</p><p>Neovascular AMD (nAMD) accounts for more than 90% of vision loss due to AMD disease, and although anti-vascular endothelial growth factor (VEGF) injections have become the first-line treatment to improve angiogenesis (<xref rid="ref-61" ref-type="bibr">Pugazhendhi et al., 2021</xref>), there are still patients who are incurable due to subretinal fibrosis (SF) (<xref rid="ref-90" ref-type="bibr">Zhang et al., 2025</xref>). Growing evidence implicates RPE cell epithelial-mesenchymal transition (EMT) as critical to SF pathogenesis in nAMD (<xref rid="ref-92" ref-type="bibr">Zhou et al., 2020</xref>). <xref rid="ref-48" ref-type="bibr">Ma et al. (2024b)</xref> found downregulation of mitochondria-associated metabolism and downregulation of carnitine palmitoyltransferase 1A (CPT1A) expression in retinal pigment epithelial cells using single-cell sequencing in a mouse nAMD model. Their findings suggest a bidirectional relationship between metabolic dysfunction and fibrosis: metabolic alterations drive fibrotic progression, while fibrosis exacerbates metabolic imbalance. Specifically, TGF&#946; signaling activation reprograms RPE metabolism, shifting from mitochondrial oxidative phosphorylation to glycolysis <italic toggle="yes">via</italic> ERK-dependent downregulation of CPT1A and other key metabolic enzymes. As CPT1A is the rate-limiting enzyme for mitochondrial fatty acid oxidation, its suppression blocks fatty acid entry into mitochondria, forcing cells into a glycolytic state reminiscent of the Warburg effect. This metabolic shift not only enables rapid ATP production to fuel EMT and extracellular matrix (ECM) deposition during fibrosis but also generates glycolytic byproducts like serine and glycine, which directly support collagen synthesis. Central to this metabolic rewiring is the mitochondrial pyruvate dehydrogenase complex (PDC), whose activity is tightly regulated by post-translational modifications. Phosphorylation of PDC&#8217;s E1&#945; subunit (PDHE1&#945;) by pyruvate dehydrogenase kinases (PDK1&#8211;4) inhibits PDC, diverting pyruvate away from mitochondrial oxidation (<xref rid="ref-56" ref-type="bibr">Park et al., 2018</xref>). Supporting this mechanism, <xref rid="ref-34" ref-type="bibr">Kim et al. (2024)</xref> demonstrated that PDK4-mediated PDHE1&#945; phosphorylation dramatically increases in RPE cells within 24&#160;h of laser-induced CNV in mice, shunting metabolism toward aerobic glycolysis. Consequently, accumulated glycolytic intermediates provide energy and biosynthetic precursors for cell proliferation and inflammation, propelling CNV progression. Critically, Pdk4 knockout mice exhibit significantly smaller CNV lesions, highlighting PDK4 inhibition as a promising therapeutic strategy for nAMD.</p><p>In AMD, elevated levels of cytokines such as TNF&#945;, TGF-&#946;2, IL-6, and IL-1&#946; in the RPE/choroid complex drive chronic inflammation, contributing to tissue injury, oxidative stress, fibrosis, and necrosis (<xref rid="ref-38" ref-type="bibr">Lee et al., 2021</xref>). <xref rid="ref-25" ref-type="bibr">Hansman et al. (2024)</xref> found that TNF&#945;, TGF-&#946;2, IL-1&#946;, and cytokine mixtures significantly elevated lactate production, glucose consumption, and extracellular acidification rates in ARPE-19 cells, primary human RPE cells (from donor eyes), and rat retinal explants, while also modulating glycolytic gene expression. These findings strongly implicate inflammatory cytokines in promoting AMD progression through metabolic reprogramming. Beyond cytokines, excessive homocysteine (Hcy) disrupts RPE structure and barrier function, promotes experimental CNV in mice (<xref rid="ref-29" ref-type="bibr">Ibrahim et al., 2016</xref>), and upregulates retinal hypoxia-inducible factor 1&#945; (HIF-1&#945;) and VEGF levels (<xref rid="ref-72" ref-type="bibr">Tawfik et al., 2014</xref>), thereby enhancing angiogenic potential in retinal endothelial cells both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="ref-52" ref-type="bibr">Mohamed et al., 2017</xref>). Further supporting this metabolic link, <xref rid="ref-67" ref-type="bibr">Samra et al. (2023)</xref> revealed that HHcy induces a Warburg-like glycolytic shift in RPE cells by upregulating glycolytic enzymes (<italic toggle="yes">e.g.</italic>, hexokinase 1 and lactate dehydrogenase), leading in cellular dysfunction and pathological CNV. Collectively, these studies establish metabolic reprogramming as a central pathogenic mechanism in AMD. Targeting these metabolic pathways may unlock novel therapeutic strategies to mitigate AMD progression.</p></sec><sec><title>Retinitis pigmentosa</title><p>Retinitis pigmentosa (RP) is an inherited retinal disease caused by mutations in several genes, leading to progressive degeneration of photoreceptors and eventual blindness (<xref rid="ref-77" ref-type="bibr">Vingolo et al., 2024</xref>). In healthy photoreceptors, the OS rely on NADPH&#8212;produced by the PPP&#8212;to synthesize phospholipids, a critical process for maintaining their structure and function. However, in RP, one of the earliest pathological hallmarks is abnormal rod photoreceptor OS development. Mutations in the phosphodiesterase-6 (<italic toggle="yes">PDE6</italic>) gene, a key regulator of photoreceptor signaling, are among the most common causes of autosomal recessive RP (<xref rid="ref-81" ref-type="bibr">Wu et al., 2016</xref>). To explore potential therapeutic strategies, <xref rid="ref-88" ref-type="bibr">Zhang et al. (2016)</xref>. Knocked out the <italic toggle="yes">sirt6</italic> gene in <italic toggle="yes">Pde6</italic>-mutant mice; they demonstrated that <italic toggle="yes">sirt6</italic> knockout preserved OS integrity, restored retinal layer morphology, and improved photoreceptor function. Mechanistically, inhibition of the <italic toggle="yes">sirt6</italic> gene was shown to enhance glycolysis by upregulating glycolysis-related transcription factors, modulating enzyme kinetics, and increasing metabolic intermediate levels, thereby shifting cellular metabolism toward glycolytic flux.</p><p>RP is characterized by the primary degeneration of rod photoreceptors, followed by the subsequent loss of cone photoreceptors (<xref rid="ref-76" ref-type="bibr">Verbakel et al., 2018</xref>). Since approximately 10% of photoreceptor OS are phagocytosed by RPE cells daily, photoreceptors require efficient membrane synthesis to sustain their structural integrity. Notably, aerobic glycolysis has been proposed as being critical for supporting their membrane biosynthesis (<xref rid="ref-63" ref-type="bibr">Rajala, 2020</xref>). PKM2, which catalyzes the final step of glycolysis (conversion of PEP to pyruvate), is highly expressed in both rod and cone photoreceptors (<xref rid="ref-79" ref-type="bibr">Weh et al., 2020</xref>). <xref rid="ref-89" ref-type="bibr">Zhang et al. (2020)</xref> found that photoreceptor function could be rescued by PKM2 knockdown. This apparent contradiction may arise from PKM2&#8217;s dual roles: its knockdown might restore glucose homeostasis by enhancing catabolic ATP production or by modulating metabolic coupling between RPE cells and photoreceptors, thereby shifting photoreceptors toward a pro-survival anabolic state. Further supporting this metabolic interplay, <xref rid="ref-64" ref-type="bibr">Rajala et al. (2018a)</xref> demonstrated that conditional knockdown of PKM2 in mouse rod photoreceptors led to the accumulation of glycolytic intermediates, reduced dark-adapted a- and b-wave amplitudes on electroretinography (ERG), and impaired rod function <italic toggle="yes">via</italic> metabolic flux analysis. Consistently, TUNEL staining revealed an increase in cell death in the retinal outer nuclear layer, indicating PKM2 loss exacerbates rod degeneration. In a parallel study published the same year, <xref rid="ref-65" ref-type="bibr">Rajala et al. (2018b)</xref> conditionally knocked out PKM2 in cone photoreceptors, observing age-dependent cone dysfunction&#8212;manifested as decreased visual b-wave amplitude, altered flicker ERG responses, cone cell loss, and OS shortening. These phenotypes correlated with the downregulation of glycolysis-, PPP-, and fatty acid biosynthesis-related genes. Strikingly, subretinal PKM2 injection partially rescued OS shortening (<xref rid="ref-7" ref-type="bibr">Chinchore et al., 2017</xref>) underscoring PKM2&#8217;s essential role in cone anabolism. Expanding on these findings, <xref rid="ref-93" ref-type="bibr">Zhu et al. (2021)</xref> reported that blue light exposure upregulated PKM2 expression in the 661W cone cell line, triggering oxidative stress and apoptosis. However, pretreatment with the PKM2 inhibitor shikonin reduced apoptosis and mitigated oxidative stress. Conversely, <xref rid="ref-83" ref-type="bibr">Wubben et al. (2020)</xref> later showed in 2020 that the PKM2 activator ML-265 regulated metabolism and suppressed apoptosis, highlighting PKM2&#8217;s context-dependent effects. Collectively, these studies establish PKM2 as a pivotal regulator of photoreceptor homeostasis, influencing metabolic reprogramming, survival, and retinal degeneration progression. Targeting PKM2-mediated pathways thus represents a promising therapeutic strategy for retinal diseases.</p></sec></sec><sec><title>Diabetic retinopathy</title><p>Diabetic retinopathy (DR) is the leading cause of visual impairment and blindness in people of working age. Metabolic reprogramming plays a key role in the DR process. In DR, persistent hyperglycemia induces mitochondrial dysfunction in RPE cells, triggering a glycolytic shift and excessive lactate production, which exacerbates photoreceptor degeneration (<xref rid="ref-87" ref-type="bibr">Yumnamcha et al., 2020</xref>). Notably, under physiological conditions, photoreceptors export lactate to fuel RPE cells and M&#252;ller glial cells. However, in DR, pathological accumulation of lactate and glutamate in M&#252;ller cells and neuronal microenvironments induces retinal excitotoxicity and photoreceptor damage (<xref rid="ref-39" ref-type="bibr">Li &amp; Puro, 2002</xref>). Furthermore, M&#252;ller cell dysfunction disrupts neurovascular interactions, compromising retinal homeostasis (<xref rid="ref-53" ref-type="bibr">Newman, 2013</xref>). Metabolic reprogramming also impairs endothelial cell barrier function, accelerating DR progression by destabilizing vascular integrity (<xref rid="ref-73" ref-type="bibr">Trudeau et al., 2010</xref>; <xref rid="ref-49" ref-type="bibr">Madsen-Bouterse et al., 2010</xref>). Targeting endothelial metabolism, <xref rid="ref-21" ref-type="bibr">Han et al. (2024)</xref> demonstrated that tSRNA-1599 suppresses angiogenesis by modulating <italic toggle="yes">HK2</italic> expression, altering glycolytic flux and metabolite dynamics. Central to DR pathogenesis, HIF-1&#945; amplifies glycolysis, exacerbating oxidative stress and neurodegeneration, particularly in photoreceptors (<xref rid="ref-40" ref-type="bibr">Li et al., 2020a</xref>; <xref rid="ref-50" ref-type="bibr">Min et al., 2021</xref>). Counteracting this cascade, <xref rid="ref-6" ref-type="bibr">Chen et al. (2024)</xref> showed that WNT inhibitory factor 1 (WIF1) mitigates photoreceptor damage by suppressing the Wnt/&#946;-catenin&#8211;HIF-1&#945;&#8211;GLUT1 axis, thereby reducing oxidative stress and preserving retinal neurons. Compounding these metabolic disruptions, high glucose and cytokines synergistically inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. While GAPDH suppression forces a metabolic shift toward oxidative phosphorylation to meet energy demands, this adaptation risks oxidative stress and mitochondrial dysfunction (<xref rid="ref-68" ref-type="bibr">Shivashankar, Lim &amp; Acosta, 2021</xref>). Emerging evidence also implicates microglial metabolic reprogramming in DR inflammation. Using multi-omics approaches, <xref rid="ref-45" ref-type="bibr">Lv et al. (2022)</xref> identified activated microglia as key drivers of early retinal inflammation, with their metabolic rewiring fueling pro-inflammatory responses (<xref rid="ref-3" ref-type="bibr">Cai, Xia &amp; Zhang, 2024</xref>). Notably, STF31 treatment reprograms inflamed microglia toward oxidative phosphorylation by blocking GLUT1-mediated glucose uptake, highlighting therapeutic potential.</p><p>Collectively, DR progression hinges on metabolic crosstalk among photoreceptors, RPE, M&#252;ller cells, endothelium, and microglia, orchestrated by oxidative stress, inflammation, and mitochondrial failure. Deciphering these mechanisms offers promise for developing targeted therapies to halt DR progression and preserve vision.</p></sec><sec><title>Uveal melanoma</title><p>Uveal melanoma (UM), an aggressive intraocular malignancy arising from melanocytes, exhibits high metastatic potential even after successful primary tumor treatment with radiation or surgery. It is concerning that the median age at diagnosis for patients with metastatic UM is approximately 61&#8211;65 years, and the 10-year mortality rate is extremely high, approaching 100% (<xref rid="ref-69" ref-type="bibr">Smit et al., 2020</xref>; <xref rid="ref-66" ref-type="bibr">Rantala et al., 2022</xref>). As a hallmark feature of cancer, metabolic reprogramming involves alterations in key pathways in UM. <xref rid="ref-58" ref-type="bibr">Peng et al. (2018)</xref> utilized TCGA pan-cancer data (including UM) to classify tumor samples into different metabolic expression subtypes through transcriptomic analysis. Their study revealed that upregulation of genes related to glycolysis, the tricarboxylic acid cycle, and energy metabolism constitutes a specific subtype pattern in UM and other cancer types, which is associated with poor patient prognosis at the pan-cancer level. Consistent with this, UM with monosomy 3 may have higher glucose uptake potential, accumulate more 18F-FDG, and show up as abnormal radioactive foci on PET/CT images (<xref rid="ref-80" ref-type="bibr">Weidmann et al., 2017</xref>). This suggests that glycolytic activity is elevated in UM tumors (<xref rid="ref-8" ref-type="bibr">Cohen et al., 2018</xref>). Critically, higher total glycolytic activity correlates with poorer median overall survival (<xref rid="ref-23" ref-type="bibr">Han, Schug &amp; Aplin, 2021</xref>). Whereas glycogen metabolism is suppressed, particularly in highly metastatic monosomy 3 UM (<xref rid="ref-75" ref-type="bibr">Vardanyan et al., 2020</xref>). These metabolic adaptations likely drive UM pathogenesis and metastasis.</p><p>Hypoxia, a key microenvironmental feature of UM, fuels malignant progression by stabilizing HIF-1&#945; (<xref rid="ref-91" ref-type="bibr">Zhao et al., 2022</xref>). HIF-1&#945; promotes tumor growth and metastasis by upregulating pro-angiogenic genes (<italic toggle="yes">e.g.</italic>, <italic toggle="yes">VEGF</italic>, <italic toggle="yes">ANGPTL4</italic>) (<xref rid="ref-27" ref-type="bibr">Hu et al., 2021</xref>), and rewiring tumor metabolism (<xref rid="ref-10" ref-type="bibr">de Heer, Jalving &amp; Harris, 2020</xref>). Notably, BNIP3&#8212;a hypoxia-inducible stress sensor regulated by HIF-1&#945;&#8212;modulates energy metabolism in UM cells (<xref rid="ref-85" ref-type="bibr">Yao et al., 2022</xref>). Under hypoxia, BNIP3 enhances mitochondrial respiration and ATP production while suppressing glycolysis (reduced glucose uptake/lactate output) (<xref rid="ref-71" ref-type="bibr">Sun et al., 2024</xref>). Mechanistically, BNIP3 acts as a mitophagy receptor, binding LC3 to clear dysfunctional mitochondria under hypoxia (<xref rid="ref-55" ref-type="bibr">Panigrahi et al., 2020</xref>). This mitochondrial optimization reduces mitochondrial ROS (mtROS), which destabilizes HIF-1&#945;, thereby inhibiting its transcriptional activation of glycolytic genes and perpetuating metabolic adaptation.</p><p>BRCA1-associated protein 1 (BAP1), a tumor suppressor gene located on chromosome 3p21.1, is frequently deleted in metastatic UM (<xref rid="ref-4" ref-type="bibr">Carbone et al., 2020</xref>). Approximately 30%&#8211;40% of primary UM cases exhibit BAP1 mutations, while more than 80% of UM cases with distant metastasis exhibit BAP1 mutations (<xref rid="ref-13" ref-type="bibr">Field et al., 2018</xref>). Recent studies have shown that loss of BAP1 in cancer cells results in critical changes in cellular metabolism (<xref rid="ref-22" ref-type="bibr">Han et al., 2021</xref>). BAP1-deficient UM tumors exhibit hyperactive OXPHOS (<xref rid="ref-23" ref-type="bibr">Han, Schug &amp; Aplin, 2021</xref>). <xref rid="ref-20" ref-type="bibr">Han et al. (2022)</xref> additionally, they reported upregulated PDC components and pyruvate dehydrogenase kinase 1 (PDHK1) in these tumors. Mechanistically, PDHK1-mediated phosphorylation of PDH diverts pyruvate toward glycolysis, and PDHK1 inhibition suppresses UM cell growth, validating metabolic targeting as a therapeutic strategy.</p><p>Metabolic reprogramming, particularly abnormal glycolysis, is a characteristic hallmark of uveal melanoma (UM) and an important prognostic indicator. <xref rid="ref-26" ref-type="bibr">Hindso et al. (2025)</xref> found that glycolysis parameters measured by <sup>1</sup><sup>8</sup>F-FDG PET/CT (metabolic tumor volume, MTV; total lesion glycolysis, TLG) measured by <sup>1</sup><sup>8</sup>F-FDG PET/CT outperform AJCC staging in predicting survival in metastatic UM, indicating that elevated glycolysis levels are associated with poor prognosis. Similarly, <xref rid="ref-18" ref-type="bibr">Guo et al. (2023</xref>) established a glycolysis-related gene signature (GRGS) comprising genes such as ISG20 and MET, which accurately predicts prognosis and is associated with immune infiltration and mutations (<italic toggle="yes">e.g.</italic>, BAP1, SF3B1). These findings highlight that metabolic rewiring not only drives the pathogenesis of UM but also provides quantifiable indicators for prognosis. Targeting these pathways may offer new therapeutic avenues for high-risk patients. For example, quercetin inhibits glycolysis in UM cells (<xref rid="ref-74" ref-type="bibr">Tura et al., 2024</xref>), while lactate, as a key metabolic regulator, reshapes the metabolic profile of UM cells through distinct mechanisms (<xref rid="ref-44" ref-type="bibr">Longhitano et al., 2022</xref>). Abnormal glycolysis serves as both a critical prognostic biomarker and a therapeutic target, reflecting tumor aggressiveness and providing avenues for intervention.</p></sec><sec><title>Glaucoma</title><p>Glaucoma is an optic neuropathy in which the main risk factors are elevated intraocular pressure (IOP) and reduced ocular perfusion. High IOP leads to damage of retinal ganglion cell (RGC) axons, manifesting in pathological features such as optic nerve head cupping and excessive deposition of ECM in the lamina cribrosa (<xref rid="ref-32" ref-type="bibr">Kang &amp; Tanna, 2021</xref>). Damaged axons release a range of signaling molecules, including cytokines and growth factors, which activate surrounding cells into a state of repair and regeneration. This process, however, may inadvertently drive fibrosis: excessive ECM deposition results in the activation of fibroblasts within the ECM, laying the groundwork for fibrosis (<xref rid="ref-43" ref-type="bibr">Liu et al., 2018</xref>). Notably, mitochondrial dysfunction and impaired cellular respiration/metabolism in fibroblasts are hallmark features of fibrosis (<xref rid="ref-41" ref-type="bibr">Li et al., 2020b</xref>). Building on this, <xref rid="ref-31" ref-type="bibr">Kamel et al. (2020)</xref> demonstrated metabolic reprogramming in glaucomatous lamina cribrosa (LC) cells. Compared to normal LC cells, glaucomatous LC cells exhibit decreased OXPHOS and increased glycolysis. Specifically, monocarboxylate transporter 1 (MCT1) and MCT4&#8212;responsible for intra- and extracellular lactate transport (<xref rid="ref-60" ref-type="bibr">Pucino, Cucchi &amp; Mauro, 2018</xref>)&#8212;are significantly upregulated in glaucomatous LC cells at both mRNA and protein levels. Additionally, enzymes involved in one-carbon and glutamine metabolism are elevated. Enhanced glycolysis rapidly generates ATP, fueling the proliferation and migration of fibrosis-associated cells and ECM synthesis, thereby promoting fibrotic progression. Previous studies have linked MCT4 upregulation to keloid fibroblasts (<xref rid="ref-54" ref-type="bibr">Okuno et al., 2018</xref>), where MCT4 co-localizes with cell surface glycoproteins that induce ECM metalloproteinases (<xref rid="ref-57" ref-type="bibr">Payen et al., 2020</xref>). Critically, the acidic microenvironment caused by elevated lactate may impair matrix metalloproteinase activity, disrupting the balance between ECM degradation and synthesis. This imbalance exacerbates ECM accumulation and accelerates fibrosis. Collectively, these findings suggest that persistent fibrotic injury in the LC arises from metabolic reprogramming; thus, future studies should evaluate whether targeting these metabolic pathways represents a viable therapeutic strategy.</p></sec><sec><title>Dry eye disease</title><p>Dry eye disease (DED) is a multifactorial disorder characterized by tear film instability, hyperosmolarity, and ocular surface inflammation (<xref rid="ref-2" ref-type="bibr">Britten-Jones et al., 2024</xref>). In China, the prevalence of DED ranges from 5% to 50%, while the incidence is as high as 31.4% (<xref rid="ref-70" ref-type="bibr">Song et al., 2018</xref>). Central to this pathology are mitochondrial respiration and glycolysis, the primary metabolic pathways for ATP production essential to normal corneal endothelial cell function (<xref rid="ref-17" ref-type="bibr">Greiner et al., 2015</xref>). Notably, monocytes infiltrating the ocular surface differentiate into inflammation-associated M1 macrophages, a process recapitulated in murine models where DED is induced by desiccation stress (<xref rid="ref-86" ref-type="bibr">You et al., 2015</xref>). Recent insights from tear metabolic profiling in DED patients revealed that tear film rupture triggers abnormal glycolysis, marked by TCA cycle overexpression (<xref rid="ref-30" ref-type="bibr">Jiang et al., 2020</xref>). Building on this, <xref rid="ref-24" ref-type="bibr">Han et al. (2023)</xref> demonstrated that hyperosmotic stress mediates glycolytic reprogramming in ocular surface epithelial cells, specifically <italic toggle="yes">via</italic> microenvironment-driven lactate accumulation and macrophage pyroptosis, which exacerbate DED-associated inflammation. Clinical data corroborate these findings: DED patients exhibit significantly elevated IL-1&#946; levels in tear fluid and upregulated pyroptosis- and glycolysis-related genes in ocular surface epithelial cells. Similarly, in murine DED models, glycolysis and pyroptosis-driven inflammation are enhanced. Mechanistically, co-culture experiments revealed that hyperosmotic stress induces glycolytic reprogramming in human corneal epithelial cells (HCECs), subsequently triggering macrophage cell death. Conversely, inhibiting HCEC glycolysis suppresses this effect. Collectively, these studies highlight glycolysis-dependent cell death as a key driver of DED pathogenesis, positioning glycolytic pathway regulators as potential therapeutic targets.</p></sec><sec><title>Graves&#8217; orbitopathy</title><p>Thyroid-associated ophthalmopathy (TAO), also known as Graves&#8217; ophthalmopathy or thyroid ophthalmopathy, is the most common extra-thyroidal manifestation of Graves&#8217; disease (GD) (<xref rid="ref-37" ref-type="bibr">Lee &amp; Kahaly, 2023</xref>) and is closely linked to oxidative stress. Recent studies suggest that oxidative stress plays a critical role in the pathogenesis of TAO. During oxidative stress, mitochondria produce excess free radicals and oxidants, disrupting the cellular redox balance. This imbalance can damage mitochondrial membranes and DNA, impairing the function of ocular tissues in TAO patients (<xref rid="ref-48" ref-type="bibr">Ma et al., 2024b</xref>). Notably, orbital fibroblasts (OFs) mediate most of these pathological changes in response to inflammatory or metabolic stimuli (<xref rid="ref-35" ref-type="bibr">&#321;acheta et al., 2019</xref>). Importantly, TAO OFs exhibit significant oxidative stress (<xref rid="ref-36" ref-type="bibr">Lanzolla, Marcocci &amp; Marin&#242;, 2020</xref>). Interestingly, in proliferating cells&#8212;particularly tumor cells&#8212;the glycolytic pathway is known to dominate. <xref rid="ref-47" ref-type="bibr">Ma et al. (2020)</xref> demonstrated that TAO OFs similarly exhibit enhanced glycolysis. Their experiments revealed that the PDK inhibitor dichloroacetic acid (DCA) suppresses TAO OF proliferation, reduces lactate production, and increases oxygen consumption. Furthermore, knockdown of PDK2&#8212;overexpressed in TAO OFs&#8212;replicated these effects, confirming its role in driving glycolytic activity. Enhanced glycolysis promotes cell proliferation, and proliferating cells may leverage this metabolic shift to bolster antioxidant defenses, thereby mitigating oxidative stress. Building on this, <xref rid="ref-46" ref-type="bibr">Ma et al. (2022)</xref> found that switching OFs from OXPHOS to glycolysis reduces reactive oxygen species (ROS) production, which enhances resistance to ferroptosis. Collectively, these findings underscore the pivotal role of glycolysis in TAO pathogenesis, highlighting glycolytic pathway components as potential therapeutic targets. Further research is needed to elucidate the detailed mechanisms by which glycolysis influences ocular disease progression.</p></sec><sec><title>Myopia</title><p>Myopia is a highly prevalent eye disorder worldwide, with adult prevalence rates reaching 10&#8211;30% in many countries. In regions of East and Southeast Asia, prevalence among young populations is strikingly higher, exceeding 80&#8211;90% (<xref rid="ref-51" ref-type="bibr">Modjtahedi et al., 2018</xref>). Myopia is characterized by excessive elongation of the ocular axial length (AL) and vitreous chamber depth (VCD), which shifts the focal point of light in front of the retina. This refractive error triggers abnormal visual signaling, prompting the retina to release tonic signaling molecules. These molecules propagate to the choroid and sclera, driving pathological scleral remodeling through aberrant metabolic processes (<xref rid="ref-1" ref-type="bibr">Baird et al., 2020</xref>). Mechanistically, <xref rid="ref-12" ref-type="bibr">Feng et al. (2024)</xref> analyzed retinal tissues in guinea pigs with form-deprivation myopia (FDM) and observed upregulation of key glycolytic rate-limiting enzymes in the FDM group. Specifically, LDH activity and lactate levels were significantly elevated compared to controls. The authors proposed that heightened glycolysis in the retina may meet the energy demands of rapid ocular elongation, while lactate could also mediate protein lactylation modifications. Extending these findings to the sclera, <xref rid="ref-42" ref-type="bibr">Lin et al. (2024)</xref> reported increased glycolysis-related enzymes and lactate in murine sclera, with PKM2 overexpression inducing myopia-like features, including AL elongation and reduced refractive power. Together, these studies suggest that metabolic reprogramming&#8212;particularly glycolytic activation&#8212;contributes to myopia progression, though deeper investigations are needed to identify clinically translatable therapeutic targets. Supporting this hypothesis, the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) suppressed FDM development in guinea pigs, demonstrating that scleral glycolysis promotes myopia, while its inhibition alleviate the condition. These collective findings underscore glycolysis reprogramming as a critical driver of myopia, offering potential targets for prevention and treatment, while advancing our understanding of its molecular and cellular mechanisms.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, our comprehensive analysis underscores the pivotal role of metabolic reprogramming in driving the progression of various ocular diseases, including AMD, RP, DR, UM, glaucoma, DED, TAO, and myopia. Across these conditions, aberrant shifts in metabolic pathways, particularly glycolysis and mitochondrial dysfunction, emerge as key pathogenic drivers, exacerbating tissue damage and inflammation. The interplay between mitochondrial dysfunction, oxidative stress, and inflammation creates a self-perpetuating cycle that destabilizes retinal homeostasis, accelerates fibrosis, and promotes neurodegeneration. Crucially, the metabolic crosstalk between retinal cells&#8212;such as photoreceptors, RPE, and M&#252;ller glia&#8212;highlights the interdependence of energy substrate availability, redox balance, and structural integrity in maintaining visual function. Targeting these metabolic alterations presents a promising therapeutic avenue to mitigate disease progression and preserve vision. For example, lactate plays a key role in metabolic regulation in the retina by activating the GPR81 receptor, promoting the survival of retinal ganglion cells, optimizing the energy metabolism of M&#252;ller cells, and reducing lactate release. These effects clearly indicate that the lactate/GPR81 signaling axis may be a potential therapeutic target. Future research should focus on elucidating the intricate molecular mechanisms underlying metabolic reprogramming in ocular diseases, exploring the potential of metabolic modulators as therapeutic agents, and developing personalized strategies to restore metabolic balance in affected tissues. Additionally, cellular metabolism is an interconnected network. In addition to glycolysis, which is the focus of this article, the reprogramming of amino acid metabolism (such as glutamine metabolism) and lipid metabolism (such as fatty acid metabolism) also plays a key role in various physiological and pathological processes and is increasingly attracting attention in the field of ophthalmology. Future research urgently needs to explore the interactions and synergistic/antagonistic effects of these different metabolic pathways in the disease-specific microenvironment of the eye, which will lay the foundation for developing more effective metabolic intervention therapies.</p></sec><sec sec-type="supplementary-material" id="supplemental-information"><title> Supplemental Information</title><supplementary-material id="supp-1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.7717/peerj.20478/supp-1</object-id><label>Supplemental Information 1</label><caption><title>PRISMA checklist</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="peerj-14-20478-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="supp-2" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.7717/peerj.20478/supp-2</object-id><label>Supplemental Information 2</label><caption><title>Metabolic reprogramming of RPE (AMD), photoreceptors (RP), microglia/RPE (DR), uveal melanoma (UM), lamina cribrosa (glaucoma), corneal endothelium (DED), orbital fibroblasts (TAO) and retina/sclera (myopia)</title><p>Image Creation Software: figdraw</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="peerj-14-20478-s002.png" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="additional-information"><title>Additional Information and Declarations</title><fn-group content-type="competing-interests"><title>Competing Interests</title><fn id="conflict-1" fn-type="COI-statement"><p>The authors declare no competing interests.</p></fn></fn-group><fn-group content-type="author-contributions"><title>Author Contributions</title><fn id="contribution-1" fn-type="con"><p><xref rid="author-1" ref-type="contrib">Xiaoqi Gong</xref> conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-2" fn-type="con"><p><xref rid="author-2" ref-type="contrib">Jiaojiao Feng</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-3" fn-type="con"><p><xref rid="author-3" ref-type="contrib">Yibo Han</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-4" fn-type="con"><p><xref rid="author-4" ref-type="contrib">Guodong Tang</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-5" fn-type="con"><p><xref rid="author-5" ref-type="contrib">Yixue Yin</xref> analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-6" fn-type="con"><p><xref rid="author-6" ref-type="contrib">Jing Li</xref> analyzed the data, prepared figures and/or tables, and approved the final draft.</p></fn><fn id="contribution-7" fn-type="con"><p><xref rid="author-7" ref-type="contrib">Yuxi Liu</xref> performed the experiments, prepared figures and/or tables, and approved the final draft.</p></fn><fn id="contribution-8" fn-type="con"><p><xref rid="author-8" ref-type="contrib">Jun Zhang</xref> performed the experiments, prepared figures and/or tables, and approved the final draft.</p></fn><fn id="contribution-9" fn-type="con"><p><xref rid="author-9" ref-type="contrib">Jike Song</xref> analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-10" fn-type="con"><p><xref rid="author-10" ref-type="contrib">Hongsheng Bi</xref> analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn></fn-group><fn-group content-type="other"><title>Data Availability</title><fn id="addinfo-1"><p>The following information was supplied regarding data availability:</p><p>Raw data was not generated in this literature review.</p></fn></fn-group></sec><ref-list content-type="authoryear"><title>References</title><ref id="ref-1"><label>Baird et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>PN</given-names></name><name name-style="western"><surname>Saw</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Lanca</surname><given-names>C</given-names></name><name name-style="western"><surname>Guggenheim</surname><given-names>JA</given-names></name><name name-style="western"><surname>Smith&#160;Iii</surname><given-names>EL</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>K-O</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P-C</given-names></name><name name-style="western"><surname>Sankaridurg</surname><given-names>P</given-names></name><name name-style="western"><surname>Chia</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>M</given-names></name><name name-style="western"><surname>Lamoureux</surname><given-names>EL</given-names></name><name name-style="western"><surname>Man</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myopia</article-title><source>Nature Reviews. Disease Primers</source><volume>6</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00231-4</pub-id><pub-id pub-id-type="pmid">33328468</pub-id></element-citation></ref><ref id="ref-2"><label>Britten-Jones et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Britten-Jones</surname><given-names>AC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MTM</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>I</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>C</given-names></name><name name-style="western"><surname>Stapleton</surname><given-names>F</given-names></name><name name-style="western"><surname>Craig</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Epidemiology and risk factors of dry eye disease: considerations for clinical management</article-title><source>Medicina</source><volume>60</volume><fpage>1458</fpage><pub-id pub-id-type="doi">10.3390/medicina60091458</pub-id><pub-id pub-id-type="pmid">39336499</pub-id><pub-id pub-id-type="pmcid">PMC11433936</pub-id></element-citation></ref><ref id="ref-3"><label>Cai, Xia &amp; Zhang (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Redox regulation of immunometabolism in microglia underpinning diabetic retinopathy</article-title><source>Antioxidants</source><volume>13</volume><fpage>423</fpage><pub-id pub-id-type="doi">10.3390/antiox13040423</pub-id><pub-id pub-id-type="pmid">38671871</pub-id><pub-id pub-id-type="pmcid">PMC11047590</pub-id></element-citation></ref><ref id="ref-4"><label>Carbone et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbone</surname><given-names>M</given-names></name><name name-style="western"><surname>Harbour</surname><given-names>JW</given-names></name><name name-style="western"><surname>Brugarolas</surname><given-names>J</given-names></name><name name-style="western"><surname>Bononi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>I</given-names></name><name name-style="western"><surname>Dey</surname><given-names>A</given-names></name><name name-style="western"><surname>Krausz</surname><given-names>T</given-names></name><name name-style="western"><surname>Pass</surname><given-names>HI</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Gaudino</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biological Mechanisms and Clinical Significance of BAP1 mutations in human cancer</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>1103</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1220</pub-id><pub-id pub-id-type="pmid">32690542</pub-id><pub-id pub-id-type="pmcid">PMC8006752</pub-id></element-citation></ref><ref id="ref-5"><label>Casson et&#160;al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casson</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wood</surname><given-names>JPM</given-names></name><name name-style="western"><surname>Han</surname><given-names>G</given-names></name><name name-style="western"><surname>Kittipassorn</surname><given-names>T</given-names></name><name name-style="western"><surname>Peet</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Chidlow</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>M-type pyruvate kinase isoforms and lactate dehydrogenase A in the mammalian retina: metabolic implications</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>57</volume><fpage>66</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-17962</pub-id><pub-id pub-id-type="pmid">26780311</pub-id></element-citation></ref><ref id="ref-6"><label>Chen et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>WNT-inhibitory factor 1-mediated glycolysis protects photoreceptor cells in diabetic retinopathy</article-title><source>Journal of Translational Medicine</source><volume>22</volume><fpage>245</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05046-5</pub-id><pub-id pub-id-type="pmid">38448948</pub-id><pub-id pub-id-type="pmcid">PMC10918886</pub-id></element-citation></ref><ref id="ref-7"><label>Chinchore et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinchore</surname><given-names>Y</given-names></name><name name-style="western"><surname>Begaj</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Drokhlyansky</surname><given-names>E</given-names></name><name name-style="western"><surname>Cepko</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glycolytic reliance promotes anabolism in photoreceptors</article-title><source>ELife</source><volume>6</volume><elocation-id>e25946</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.25946</pub-id><pub-id pub-id-type="pmid">28598329</pub-id><pub-id pub-id-type="pmcid">PMC5499945</pub-id></element-citation></ref><ref id="ref-8"><label>Cohen et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>VML</given-names></name><name name-style="western"><surname>Pavlidou</surname><given-names>E</given-names></name><name name-style="western"><surname>DaCosta</surname><given-names>J</given-names></name><name name-style="western"><surname>Arora</surname><given-names>AK</given-names></name><name name-style="western"><surname>Szyszko</surname><given-names>T</given-names></name><name name-style="western"><surname>Sagoo</surname><given-names>MS</given-names></name><name name-style="western"><surname>Szlosarek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Staging uveal melanoma with whole-body positron-emission tomography/computed tomography and abdominal ultrasound: low incidence of metastatic disease, high incidence of second primary cancers</article-title><source>Middle East African Journal of Ophthalmology</source><volume>25</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.4103/meajo.MEAJO_96_18</pub-id><pub-id pub-id-type="pmid">30122854</pub-id><pub-id pub-id-type="pmcid">PMC6071338</pub-id></element-citation></ref><ref id="ref-9"><label>Curcio, Medeiros &amp; Millican (1996)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curcio</surname><given-names>CA</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>NE</given-names></name><name name-style="western"><surname>Millican</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Photoreceptor loss in age-related macular degeneration</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>37</volume><fpage>1236</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">8641827</pub-id></element-citation></ref><ref id="ref-10"><label>De&#160;Heer, Jalving &amp; Harris (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De&#160;Heer</surname><given-names>EC</given-names></name><name name-style="western"><surname>Jalving</surname><given-names>M</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>5074</fpage><lpage>5087</lpage><pub-id pub-id-type="doi">10.1172/JCI137552</pub-id><pub-id pub-id-type="pmid">32870818</pub-id><pub-id pub-id-type="pmcid">PMC7524491</pub-id></element-citation></ref><ref id="ref-11"><label>Fabre et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabre</surname><given-names>M</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>L</given-names></name><name name-style="western"><surname>Lamaa</surname><given-names>D</given-names></name><name name-style="western"><surname>Baillif</surname><given-names>S</given-names></name><name name-style="western"><surname>Pag&#232;s</surname><given-names>G</given-names></name><name name-style="western"><surname>Demange</surname><given-names>L</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>C</given-names></name><name name-style="western"><surname>Benhida</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Recent advances in age-related macular degeneration therapies</article-title><source>Molecules</source><volume>27</volume><fpage>5089</fpage><pub-id pub-id-type="doi">10.3390/molecules27165089</pub-id><pub-id pub-id-type="pmid">36014339</pub-id><pub-id pub-id-type="pmcid">PMC9414333</pub-id></element-citation></ref><ref id="ref-12"><label>Feng et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Bi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Lactylome analysis reveals potential target modified proteins in the retina of form-deprivation myopia</article-title><source>IScience</source><volume>27</volume><elocation-id>110606</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2024.110606</pub-id><pub-id pub-id-type="pmid">39246443</pub-id><pub-id pub-id-type="pmcid">PMC11379675</pub-id></element-citation></ref><ref id="ref-13"><label>Field et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Field</surname><given-names>MG</given-names></name><name name-style="western"><surname>Durante</surname><given-names>MA</given-names></name><name name-style="western"><surname>Anbunathan</surname><given-names>H</given-names></name><name name-style="western"><surname>Cai</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Decatur</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bowcock</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kurtenbach</surname><given-names>S</given-names></name><name name-style="western"><surname>Harbour</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Punctuated evolution of canonical genomic aberrations in uveal melanoma</article-title><source>Nature Communications</source><volume>9</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02428-w</pub-id><pub-id pub-id-type="pmcid">PMC5760704</pub-id><pub-id pub-id-type="pmid">29317634</pub-id></element-citation></ref><ref id="ref-14"><label>Fisher &amp; Ferrington (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>CR</given-names></name><name name-style="western"><surname>Ferrington</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Perspective on AMD pathobiology: a bioenergetic crisis in the RPE</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>59</volume><fpage>AMD41</fpage><lpage>AMD47</lpage><pub-id pub-id-type="doi">10.1167/iovs.18-24289</pub-id><pub-id pub-id-type="pmid">30025108</pub-id><pub-id pub-id-type="pmcid">PMC5989860</pub-id></element-citation></ref><ref id="ref-15"><label>Fleckenstein, Schmitz-Valckenberg &amp; Chakravarthy (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleckenstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmitz-Valckenberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Age-related macular degeneration: a review</article-title><source>Journal of the American Medical Association</source><volume>331</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.26074</pub-id><pub-id pub-id-type="pmid">38193957</pub-id></element-citation></ref><ref id="ref-16"><label>Golestaneh et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golestaneh</surname><given-names>N</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y-Y</given-names></name><name name-style="western"><surname>Stoleru</surname><given-names>GL</given-names></name><name name-style="western"><surname>Theos</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration</article-title><source>Cell Death &amp; Disease</source><volume>8</volume><elocation-id>e2537</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.453</pub-id><pub-id pub-id-type="pmid">28055007</pub-id><pub-id pub-id-type="pmcid">PMC5386365</pub-id></element-citation></ref><ref id="ref-17"><label>Greiner et&#160;al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greiner</surname><given-names>MA</given-names></name><name name-style="western"><surname>Burckart</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wagoner</surname><given-names>MD</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>GA</given-names></name><name name-style="western"><surname>Reed</surname><given-names>CR</given-names></name><name name-style="western"><surname>Liaboe</surname><given-names>CA</given-names></name><name name-style="western"><surname>Flamme-Wiese</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>MB</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>RF</given-names></name><name name-style="western"><surname>Kardon</surname><given-names>RH</given-names></name><name name-style="western"><surname>Goins</surname><given-names>KM</given-names></name><name name-style="western"><surname>Aldrich</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regional assessment of energy-producing metabolic activity in the endothelium of donor corneas</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>56</volume><fpage>2803</fpage><lpage>2810</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-16442</pub-id><pub-id pub-id-type="pmid">26024071</pub-id></element-citation></ref><ref id="ref-18"><label>Guo et&#160;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A novel glycolysis-related signature for predicting the prognosis and immune infiltration of uveal melanoma</article-title><source>Ophthalmic Research</source><volume>66</volume><fpage>692</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1159/000529818</pub-id><pub-id pub-id-type="pmid">36858025</pub-id></element-citation></ref><ref id="ref-19"><label>Guymer &amp; Campbell (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guymer</surname><given-names>RH</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Age-related macular degeneration</article-title><source>Lancet</source><volume>401</volume><fpage>1459</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)02609-5</pub-id><pub-id pub-id-type="pmid">36996856</pub-id></element-citation></ref><ref id="ref-20"><label>Han et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>A</given-names></name><name name-style="western"><surname>Chua</surname><given-names>V</given-names></name><name name-style="western"><surname>Baqai</surname><given-names>U</given-names></name><name name-style="western"><surname>Purwin</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Bechtel</surname><given-names>N</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>E</given-names></name><name name-style="western"><surname>Tiago</surname><given-names>M</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>E</given-names></name><name name-style="western"><surname>Speicher</surname><given-names>DW</given-names></name><name name-style="western"><surname>Schug</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Harbour</surname><given-names>JW</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma</article-title><source>Oncogene</source><volume>41</volume><fpage>1129</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-02154-0</pub-id><pub-id pub-id-type="pmid">35046531</pub-id><pub-id pub-id-type="pmcid">PMC9066178</pub-id></element-citation></ref><ref id="ref-21"><label>Han et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L-J</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Tong</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>X-M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Targeting endothelial glycolytic reprogramming by tsRNA-1599 for ocular anti-angiogenesis therapy</article-title><source>Theranostics</source><volume>14</volume><fpage>3509</fpage><lpage>3525</lpage><pub-id pub-id-type="doi">10.7150/thno.96946</pub-id><pub-id pub-id-type="pmid">38948065</pub-id><pub-id pub-id-type="pmcid">PMC11209708</pub-id></element-citation></ref><ref id="ref-22"><label>Han et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>A</given-names></name><name name-style="western"><surname>Purwin</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Bechtel</surname><given-names>N</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><name name-style="western"><surname>Chua</surname><given-names>V</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>E</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>Schug</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Speicher</surname><given-names>DW</given-names></name><name name-style="western"><surname>Harbour</surname><given-names>JW</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors</article-title><source>Oncogene</source><volume>40</volume><issue>3</issue><fpage>618</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01554-y</pub-id><pub-id pub-id-type="pmid">33208912</pub-id><pub-id pub-id-type="pmcid">PMC7856044</pub-id></element-citation></ref><ref id="ref-23"><label>Han, Schug &amp; Aplin (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>A</given-names></name><name name-style="western"><surname>Schug</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolic alterations and therapeutic opportunities in rare forms of melanoma</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.05.005</pub-id><pub-id pub-id-type="pmid">34127435</pub-id><pub-id pub-id-type="pmcid">PMC8295200</pub-id></element-citation></ref><ref id="ref-24"><label>Han et&#160;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hyperosmolarity promotes macrophage pyroptosis by driving the glycolytic reprogramming of corneal epithelial cells in dry eye disease</article-title><source>Frontiers of Medicine</source><volume>17</volume><fpage>781</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1007/s11684-023-0986-x</pub-id><pub-id pub-id-type="pmid">37266854</pub-id></element-citation></ref><ref id="ref-25"><label>Hansman et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JR</given-names></name><name name-style="western"><surname>Casson</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Peet</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Metabolic reprogramming of the retinal pigment epithelium by cytokines associated with age-related macular degeneration</article-title><source>Bioscience Reports</source><volume>44</volume><elocation-id>BSR20231904</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20231904</pub-id><pub-id pub-id-type="pmid">38567515</pub-id><pub-id pub-id-type="pmcid">PMC11043024</pub-id></element-citation></ref><ref id="ref-26"><label>Hindso et&#160;al. (2025)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hindso</surname><given-names>TG</given-names></name><name name-style="western"><surname>Martinussen</surname><given-names>T</given-names></name><name name-style="western"><surname>Bjerrum</surname><given-names>CW</given-names></name><name name-style="western"><surname>Keller</surname><given-names>SH</given-names></name><name name-style="western"><surname>Loft</surname><given-names>A</given-names></name><name name-style="western"><surname>Sj&#248;l</surname><given-names>MB</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>K</given-names></name><name name-style="western"><surname>Faber</surname><given-names>C</given-names></name><name name-style="western"><surname>Donia</surname><given-names>M</given-names></name><name name-style="western"><surname>Svane</surname><given-names>IM</given-names></name><name name-style="western"><surname>Ellebaek</surname><given-names>E</given-names></name><name name-style="western"><surname>Heegaard</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiilgaard</surname><given-names>JF</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma</article-title><source>Scientific Reports</source><volume>15</volume><fpage>4110</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-88625-w</pub-id><pub-id pub-id-type="pmid">39901052</pub-id><pub-id pub-id-type="pmcid">PMC11790917</pub-id></element-citation></ref><ref id="ref-27"><label>Hu et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Babapoor-Farrokhran</surname><given-names>S</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>M</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>M</given-names></name><name name-style="western"><surname>Puchner</surname><given-names>B</given-names></name><name name-style="western"><surname>Kashiwabuchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Asnaghi</surname><given-names>L</given-names></name><name name-style="western"><surname>Handa</surname><given-names>JT</given-names></name><name name-style="western"><surname>Merbs</surname><given-names>S</given-names></name><name name-style="western"><surname>Eberhart</surname><given-names>CG</given-names></name><name name-style="western"><surname>Semenza</surname><given-names>GL</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>S</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Correction: hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma</article-title><source>Oncotarget</source><volume>12</volume><fpage>519</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27780</pub-id><pub-id pub-id-type="pmid">33747364</pub-id><pub-id pub-id-type="pmcid">PMC7939528</pub-id></element-citation></ref><ref id="ref-28"><label>Hu et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Tumor energy metabolism: implications for therapeutic targets</article-title><source>Molecular Biomedicine</source><volume>5</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s43556-024-00229-4</pub-id><pub-id pub-id-type="pmid">39609317</pub-id><pub-id pub-id-type="pmcid">PMC11604893</pub-id></element-citation></ref><ref id="ref-29"><label>Ibrahim et&#160;al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Mander</surname><given-names>S</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>KA</given-names></name><name name-style="western"><surname>Elsherbiny</surname><given-names>NM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SB</given-names></name><name name-style="western"><surname>Al-Shabrawey</surname><given-names>M</given-names></name><name name-style="western"><surname>Tawfik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hyperhomocysteinemia disrupts retinal pigment epithelial structure and function with features of age-related macular degeneration</article-title><source>Oncotarget</source><volume>7</volume><fpage>8532</fpage><lpage>8545</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7384</pub-id><pub-id pub-id-type="pmid">26885895</pub-id><pub-id pub-id-type="pmcid">PMC4890985</pub-id></element-citation></ref><ref id="ref-30"><label>Jiang et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A set of global metabolomic biomarker candidates to predict the risk of dry eye disease</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><fpage>344</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.00344</pub-id><pub-id pub-id-type="pmid">32582687</pub-id><pub-id pub-id-type="pmcid">PMC7295093</pub-id></element-citation></ref><ref id="ref-31"><label>Kamel et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamel</surname><given-names>K</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Zhdanov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Papkovsky</surname><given-names>DB</given-names></name><name name-style="western"><surname>Clark</surname><given-names>AF</given-names></name><name name-style="western"><surname>Stamer</surname><given-names>WD</given-names></name><name name-style="western"><surname>Irnaten</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reduced oxidative phosphorylation and increased glycolysis in human glaucoma lamina cribrosa cells</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>61</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1167/iovs.61.13.4</pub-id><pub-id pub-id-type="pmcid">PMC7645202</pub-id><pub-id pub-id-type="pmid">33137197</pub-id></element-citation></ref><ref id="ref-32"><label>Kang &amp; Tanna (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>JM</given-names></name><name name-style="western"><surname>Tanna</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glaucoma</article-title><source>The Medical Clinics of North America</source><volume>105</volume><fpage>493</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2021.01.004</pub-id><pub-id pub-id-type="pmid">33926643</pub-id></element-citation></ref><ref id="ref-33"><label>Kanow et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanow</surname><given-names>MA</given-names></name><name name-style="western"><surname>Giarmarco</surname><given-names>MM</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>CS</given-names></name><name name-style="western"><surname>Tsantilas</surname><given-names>K</given-names></name><name name-style="western"><surname>Engel</surname><given-names>AL</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Linton</surname><given-names>JD</given-names></name><name name-style="western"><surname>Farnsworth</surname><given-names>CC</given-names></name><name name-style="western"><surname>Sloat</surname><given-names>SR</given-names></name><name name-style="western"><surname>Rountree</surname><given-names>A</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>IR</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Parker</surname><given-names>ED</given-names></name><name name-style="western"><surname>Brockerhoff</surname><given-names>SE</given-names></name><name name-style="western"><surname>Sadilek</surname><given-names>M</given-names></name><name name-style="western"><surname>Chao</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biochemical adaptations of the retina and retinal pigment epithelium support a metabolic ecosystem in the vertebrate eye</article-title><source>ELife</source><volume>6</volume><elocation-id>e28899</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.28899</pub-id><pub-id pub-id-type="pmid">28901286</pub-id><pub-id pub-id-type="pmcid">PMC5617631</pub-id></element-citation></ref><ref id="ref-34"><label>Kim et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Son</surname><given-names>J</given-names></name><name name-style="western"><surname>Pagire</surname><given-names>HS</given-names></name><name name-style="western"><surname>Pagire</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JH</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I-K</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration</article-title><source>Cell Death &amp; Disease</source><volume>15</volume><fpage>582</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06968-0</pub-id><pub-id pub-id-type="pmid">39122684</pub-id><pub-id pub-id-type="pmcid">PMC11316003</pub-id></element-citation></ref><ref id="ref-35"><label>&#321;acheta et&#160;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#321;acheta</surname><given-names>D</given-names></name><name name-style="western"><surname>Mi&#347;kiewicz</surname><given-names>P</given-names></name><name name-style="western"><surname>G&#322;uszko</surname><given-names>A</given-names></name><name name-style="western"><surname>Nowicka</surname><given-names>G</given-names></name><name name-style="western"><surname>Struga</surname><given-names>M</given-names></name><name name-style="western"><surname>Kantor</surname><given-names>I</given-names></name><name name-style="western"><surname>Po&#347;lednik</surname><given-names>KB</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>S</given-names></name><name name-style="western"><surname>Szczepa&#324;ski</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immunological aspects of graves&#8217; ophthalmopathy</article-title><source>BioMed Research International</source><volume>2019</volume><elocation-id>7453260</elocation-id><pub-id pub-id-type="doi">10.1155/2019/7453260</pub-id><pub-id pub-id-type="pmid">31781640</pub-id><pub-id pub-id-type="pmcid">PMC6875285</pub-id></element-citation></ref><ref id="ref-36"><label>Lanzolla, Marcocci &amp; Marin&#242; (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanzolla</surname><given-names>G</given-names></name><name name-style="western"><surname>Marcocci</surname><given-names>C</given-names></name><name name-style="western"><surname>Marin&#242;</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oxidative stress in graves disease and graves orbitopathy</article-title><source>European Thyroid Journal</source><volume>9</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1159/000509615</pub-id><pub-id pub-id-type="pmcid">PMC7802440</pub-id><pub-id pub-id-type="pmid">33511084</pub-id></element-citation></ref><ref id="ref-37"><label>Lee &amp; Kahaly (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>ACH</given-names></name><name name-style="western"><surname>Kahaly</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pathophysiology of thyroid-associated orbitopathy</article-title><source>Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism</source><volume>37</volume><elocation-id>101620</elocation-id><pub-id pub-id-type="doi">10.1016/j.beem.2022.101620</pub-id><pub-id pub-id-type="pmid">35181241</pub-id></element-citation></ref><ref id="ref-38"><label>Lee et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Copland</surname><given-names>DA</given-names></name><name name-style="western"><surname>Dick</surname><given-names>AD</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration</article-title><source>Journal of Neuroinflammation</source><volume>18</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12974-021-02088-0</pub-id><pub-id pub-id-type="pmid">33482879</pub-id><pub-id pub-id-type="pmcid">PMC7821689</pub-id></element-citation></ref><ref id="ref-39"><label>Li &amp; Puro (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Puro</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Diabetes-induced dysfunction of the glutamate transporter in retinal M&#252;ller cells</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>43</volume><fpage>3109</fpage><lpage>3116</lpage><pub-id pub-id-type="pmid">12202536</pub-id></element-citation></ref><ref id="ref-40"><label>Li et&#160;al. (2020a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X-Y</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Hypoxia-inducible factor-1&#945;: a promising therapeutic target for vasculopathy in diabetic retinopathy</article-title><source>Pharmacological Research</source><volume>159</volume><elocation-id>104924</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104924</pub-id><pub-id pub-id-type="pmid">32464323</pub-id></element-citation></ref><ref id="ref-41"><label>Li et&#160;al. (2020b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Mitochondrial dysfunction in fibrotic diseases</article-title><source>Cell Death Discovery</source><volume>6</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1038/s41420-020-00316-9</pub-id><pub-id pub-id-type="pmid">32963808</pub-id><pub-id pub-id-type="pmcid">PMC7474731</pub-id></element-citation></ref><ref id="ref-42"><label>Lin et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Su</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Di</surname><given-names>M</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Augmentation of scleral glycolysis promotes myopia through histone lactylation</article-title><source>Cell Metabolism</source><comment>S1550-4131(23)00474&#8211;6</comment><pub-id pub-id-type="doi">10.1016/j.cmet.2023.12.023</pub-id><pub-id pub-id-type="pmid">38232735</pub-id></element-citation></ref><ref id="ref-43"><label>Liu et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>McNally</surname><given-names>S</given-names></name><name name-style="western"><surname>Kilpatrick</surname><given-names>JI</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>SP</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aging and ocular tissue stiffness in glaucoma</article-title><source>Survey of Ophthalmology</source><volume>63</volume><fpage>56</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2017.06.007</pub-id><pub-id pub-id-type="pmid">28666629</pub-id></element-citation></ref><ref id="ref-44"><label>Longhitano et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Longhitano</surname><given-names>L</given-names></name><name name-style="western"><surname>Giallongo</surname><given-names>S</given-names></name><name name-style="western"><surname>Orlando</surname><given-names>L</given-names></name><name name-style="western"><surname>Broggi</surname><given-names>G</given-names></name><name name-style="western"><surname>Longo</surname><given-names>A</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A</given-names></name><name name-style="western"><surname>Caltabiano</surname><given-names>R</given-names></name><name name-style="western"><surname>Giallongo</surname><given-names>C</given-names></name><name name-style="western"><surname>Barbagallo</surname><given-names>I</given-names></name><name name-style="western"><surname>Di&#160;Rosa</surname><given-names>M</given-names></name><name name-style="western"><surname>Giuffrida</surname><given-names>R</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>R</given-names></name><name name-style="western"><surname>Volti</surname><given-names>GLi</given-names></name><name name-style="western"><surname>Vicario</surname><given-names>N</given-names></name><name name-style="western"><surname>Tibullo</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lactate rewrites the metabolic reprogramming of uveal melanoma cells and induces quiescence phenotype</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.3390/ijms24010024</pub-id><pub-id pub-id-type="pmid">36613471</pub-id><pub-id pub-id-type="pmcid">PMC9820521</pub-id></element-citation></ref><ref id="ref-45"><label>Lv et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>K</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jian</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Integrated multi-omics reveals the activated retinal microglia with intracellular metabolic reprogramming contributes to inflammation in STZ-induced early diabetic retinopathy</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>942768</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.942768</pub-id><pub-id pub-id-type="pmid">36119084</pub-id><pub-id pub-id-type="pmcid">PMC9479211</pub-id></element-citation></ref><ref id="ref-46"><label>Ma et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>R</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>AR</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Insights into ferroptosis: targeting glycolysis to treat graves&#8217; orbitopathy</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>107</volume><fpage>1994</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac163</pub-id><pub-id pub-id-type="pmid">35303084</pub-id></element-citation></ref><ref id="ref-47"><label>Ma et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>R</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>A</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PDK2-enhanced glycolysis promotes fibroblast proliferation in thyroid-associated ophthalmopathy</article-title><source>Journal of Molecular Endocrinology</source><volume>65</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1530/JME-20-0143</pub-id><pub-id pub-id-type="pmid">33086191</pub-id></element-citation></ref><ref id="ref-48"><label>Ma et&#160;al. (2024b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Hara</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Panzarin</surname><given-names>C</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>CM</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>CT</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J-X</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024b</year><article-title>Deficient RPE mitochondrial energetics leads to subretinal fibrosis in age-related neovascular macular degeneration</article-title><source>Communications Biology</source><volume>7</volume><fpage>1075</fpage><pub-id pub-id-type="doi">10.1038/s42003-024-06773-7</pub-id><pub-id pub-id-type="pmid">39223298</pub-id><pub-id pub-id-type="pmcid">PMC11369096</pub-id></element-citation></ref><ref id="ref-49"><label>Madsen-Bouterse et&#160;al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madsen-Bouterse</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>G</given-names></name><name name-style="western"><surname>Kanwar</surname><given-names>M</given-names></name><name name-style="western"><surname>Kowluru</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression</article-title><source>Antioxidants &amp; Redox Signaling</source><volume>13</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.2932</pub-id><pub-id pub-id-type="pmid">20088705</pub-id><pub-id pub-id-type="pmcid">PMC2935337</pub-id></element-citation></ref><ref id="ref-50"><label>Min et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>T</given-names></name><name name-style="western"><surname>Roux</surname><given-names>M</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Tudzarova</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Role of HIF1&#945;-PFKFB3 Pathway in Diabetic Retinopathy</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>106</volume><fpage>2505</fpage><lpage>2519</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgab362</pub-id><pub-id pub-id-type="pmid">34019671</pub-id><pub-id pub-id-type="pmcid">PMC8372643</pub-id></element-citation></ref><ref id="ref-51"><label>Modjtahedi et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modjtahedi</surname><given-names>BS</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>FL</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>DG</given-names></name><name name-style="western"><surname>Fong</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Public health burden and potential interventions for Myopia</article-title><source>Ophthalmology</source><volume>125</volume><fpage>628</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2018.01.033</pub-id><pub-id pub-id-type="pmid">29681290</pub-id></element-citation></ref><ref id="ref-52"><label>Mohamed et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamed</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>I</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>H</given-names></name><name name-style="western"><surname>Elsherbiny</surname><given-names>NM</given-names></name><name name-style="western"><surname>Fulzele</surname><given-names>S</given-names></name><name name-style="western"><surname>Elmasry</surname><given-names>K</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SB</given-names></name><name name-style="western"><surname>Al-Shabrawey</surname><given-names>M</given-names></name><name name-style="western"><surname>Tawfik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hyperhomocysteinemia alters retinal endothelial cells barrier function and angiogenic potential <italic toggle="yes">via</italic> activation of oxidative stress</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>11952</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-09731-y</pub-id><pub-id pub-id-type="pmid">28931831</pub-id><pub-id pub-id-type="pmcid">PMC5607263</pub-id></element-citation></ref><ref id="ref-53"><label>Newman (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>33</volume><fpage>1685</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2013.145</pub-id><pub-id pub-id-type="pmid">23963372</pub-id><pub-id pub-id-type="pmcid">PMC3824187</pub-id></element-citation></ref><ref id="ref-54"><label>Okuno et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuno</surname><given-names>R</given-names></name><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eid</surname><given-names>N</given-names></name><name name-style="western"><surname>Otsuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Upregulation of autophagy and glycolysis markers in keloid hypoxic-zone fibroblasts: morphological characteristics and implications</article-title><source>Histology and Histopathology</source><volume>33</volume><fpage>1075</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.14670/HH-18-005</pub-id><pub-id pub-id-type="pmid">29809274</pub-id></element-citation></ref><ref id="ref-55"><label>Panigrahi et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panigrahi</surname><given-names>DP</given-names></name><name name-style="western"><surname>Praharaj</surname><given-names>PP</given-names></name><name name-style="western"><surname>Bhol</surname><given-names>CS</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>KK</given-names></name><name name-style="western"><surname>Patra</surname><given-names>S</given-names></name><name name-style="western"><surname>Behera</surname><given-names>BP</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bhutia</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics</article-title><source>Seminars in Cancer Biology</source><volume>66</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.07.015</pub-id><pub-id pub-id-type="pmid">31351198</pub-id></element-citation></ref><ref id="ref-56"><label>Park et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Min</surname><given-names>BK</given-names></name><name name-style="western"><surname>Ha</surname><given-names>CM</given-names></name><name name-style="western"><surname>Thoudam</surname><given-names>T</given-names></name><name name-style="western"><surname>Park</surname><given-names>BY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>IK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of the pyruvate dehydrogenase complex in metabolic remodeling: differential pyruvate dehydrogenase complex functions in metabolism</article-title><source>Diabetes &amp; Metabolism Journal</source><volume>42</volume><fpage>270</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.4093/dmj.2018.0101</pub-id><pub-id pub-id-type="pmid">30136450</pub-id><pub-id pub-id-type="pmcid">PMC6107359</pub-id></element-citation></ref><ref id="ref-57"><label>Payen et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payen</surname><given-names>VL</given-names></name><name name-style="western"><surname>Mina</surname><given-names>E</given-names></name><name name-style="western"><surname>Van&#160;H&#233;e</surname><given-names>VF</given-names></name><name name-style="western"><surname>Porporato</surname><given-names>PE</given-names></name><name name-style="western"><surname>Sonveaux</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Monocarboxylate transporters in cancer</article-title><source>Molecular Metabolism</source><volume>33</volume><fpage>48</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.07.006</pub-id><pub-id pub-id-type="pmid">31395464</pub-id><pub-id pub-id-type="pmcid">PMC7056923</pub-id></element-citation></ref><ref id="ref-58"><label>Peng et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Farshidfar</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Mojumdar</surname><given-names>K</given-names></name><name name-style="western"><surname>Du</surname><given-names>D</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>GV</given-names></name><name name-style="western"><surname>Birsoy</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>C</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>JN</given-names></name><collab>Cancer Genome Atlas Research&#160;Network</collab><name name-style="western"><surname>Bathe</surname><given-names>OF</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers</article-title><source>Cell Reports</source><volume>23</volume><fpage>255</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.077</pub-id><pub-id pub-id-type="pmid">29617665</pub-id><pub-id pub-id-type="pmcid">PMC5916795</pub-id></element-citation></ref><ref id="ref-59"><label>Petit et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petit</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Cipi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Zieger</surname><given-names>M</given-names></name><name name-style="western"><surname>Hay</surname><given-names>N</given-names></name><name name-style="western"><surname>Punzo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aerobic glycolysis is essential for normal rod function and controls secondary cone death in retinitis pigmentosa</article-title><source>Cell Reports</source><volume>23</volume><fpage>2629</fpage><lpage>2642</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.111</pub-id><pub-id pub-id-type="pmid">29847794</pub-id><pub-id pub-id-type="pmcid">PMC5997286</pub-id></element-citation></ref><ref id="ref-60"><label>Pucino, Cucchi &amp; Mauro (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pucino</surname><given-names>V</given-names></name><name name-style="western"><surname>Cucchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Mauro</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lactate transporters as therapeutic targets in cancer and inflammatory diseases</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>22</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1080/14728222.2018.1511706</pub-id><pub-id pub-id-type="pmid">30106309</pub-id></element-citation></ref><ref id="ref-61"><label>Pugazhendhi et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugazhendhi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>M</given-names></name><name name-style="western"><surname>Jairam</surname><given-names>P</given-names></name><name name-style="western"><surname>Ambati</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><fpage>1170</fpage><pub-id pub-id-type="doi">10.3390/ijms22031170</pub-id><pub-id pub-id-type="pmid">33504013</pub-id><pub-id pub-id-type="pmcid">PMC7866170</pub-id></element-citation></ref><ref id="ref-62"><label>Rabinowitz &amp; Enerb&#228;ck (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabinowitz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Enerb&#228;ck</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lactate: the ugly duckling of energy metabolism</article-title><source>Nature Metabolism</source><volume>2</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-0243-4</pub-id><pub-id pub-id-type="pmcid">PMC7983055</pub-id><pub-id pub-id-type="pmid">32694798</pub-id></element-citation></ref><ref id="ref-63"><label>Rajala (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajala</surname><given-names>RVS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aerobic glycolysis in the retina: functional roles of pyruvate kinase isoforms</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><fpage>266</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.00266</pub-id><pub-id pub-id-type="pmid">32426353</pub-id><pub-id pub-id-type="pmcid">PMC7203425</pub-id></element-citation></ref><ref id="ref-64"><label>Rajala et&#160;al. (2018a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajala</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Brush</surname><given-names>RS</given-names></name><name name-style="western"><surname>Tsantilas</surname><given-names>K</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>CSR</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Linton</surname><given-names>JD</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>JB</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>RE</given-names></name><name name-style="western"><surname>Rajala</surname><given-names>RVS</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Pyruvate kinase M2 regulates photoreceptor structure, function, and viability</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><fpage>240</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0296-4</pub-id><pub-id pub-id-type="pmid">29445082</pub-id><pub-id pub-id-type="pmcid">PMC5833680</pub-id></element-citation></ref><ref id="ref-65"><label>Rajala et&#160;al. (2018b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajala</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Soni</surname><given-names>K</given-names></name><name name-style="western"><surname>Rajala</surname><given-names>RVS</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Pyruvate kinase M2 isoform deletion in cone photoreceptors results in age-related cone degeneration</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><fpage>737</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0712-9</pub-id><pub-id pub-id-type="pmid">29970877</pub-id><pub-id pub-id-type="pmcid">PMC6030055</pub-id></element-citation></ref><ref id="ref-66"><label>Rantala et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rantala</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hernberg</surname><given-names>MM</given-names></name><name name-style="western"><surname>Piperno-Neumann</surname><given-names>S</given-names></name><name name-style="western"><surname>Grossniklaus</surname><given-names>HE</given-names></name><name name-style="western"><surname>Kivel&#228;</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Metastatic uveal melanoma: the final frontier</article-title><source>Progress in Retinal and Eye Research</source><volume>90</volume><elocation-id>101041</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2022.101041</pub-id><pub-id pub-id-type="pmid">34999237</pub-id></element-citation></ref><ref id="ref-67"><label>Samra et&#160;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samra</surname><given-names>YA</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rajpurohit</surname><given-names>P</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>R</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Kaddour-Djebbar</surname><given-names>I</given-names></name><name name-style="western"><surname>Tawfik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Warburg effect as a novel mechanism for homocysteine-induced features of age-related macular degeneration</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><fpage>1071</fpage><pub-id pub-id-type="doi">10.3390/ijms24021071</pub-id><pub-id pub-id-type="pmid">36674587</pub-id><pub-id pub-id-type="pmcid">PMC9865636</pub-id></element-citation></ref><ref id="ref-68"><label>Shivashankar, Lim &amp; Acosta (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shivashankar</surname><given-names>G</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JC</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glyceraldehyde-3-phosphate dehydrogenase and glutamine synthetase inhibition in the presence of pro-inflammatory cytokines contribute to the metabolic imbalance of diabetic retinopathy</article-title><source>Experimental Eye Research</source><volume>213</volume><elocation-id>108845</elocation-id><pub-id pub-id-type="doi">10.1016/j.exer.2021.108845</pub-id><pub-id pub-id-type="pmid">34800480</pub-id></element-citation></ref><ref id="ref-69"><label>Smit et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smit</surname><given-names>KN</given-names></name><name name-style="western"><surname>Jager</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Klein</surname><given-names>Ade</given-names></name><name name-style="western"><surname>Kili&#231;</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Uveal melanoma: towards a molecular understanding</article-title><source>Progress in Retinal and Eye Research</source><volume>75</volume><elocation-id>100800</elocation-id><pub-id pub-id-type="doi">10.1016/j.preteyeres.2019.100800</pub-id><pub-id pub-id-type="pmid">31563544</pub-id></element-citation></ref><ref id="ref-70"><label>Song et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>P</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Rudan</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis</article-title><source>Journal of Global Health</source><volume>8</volume><elocation-id>020503</elocation-id><pub-id pub-id-type="doi">10.7189/jogh.08.020503</pub-id><pub-id pub-id-type="pmid">30206477</pub-id><pub-id pub-id-type="pmcid">PMC6122008</pub-id></element-citation></ref><ref id="ref-71"><label>Sun et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name><name name-style="western"><surname>Xue</surname><given-names>K</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming</article-title><source>Autophagy</source><volume>21</volume><issue>1</issue><fpage>191</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1080/15548627.2024.2395142</pub-id><pub-id pub-id-type="pmid">39265983</pub-id><pub-id pub-id-type="pmcid">PMC11702930</pub-id></element-citation></ref><ref id="ref-72"><label>Tawfik et&#160;al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tawfik</surname><given-names>A</given-names></name><name name-style="western"><surname>Markand</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Shabrawey</surname><given-names>M</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>JN</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J</given-names></name><name name-style="western"><surname>Bearden</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ganapathy</surname><given-names>V</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alterations of retinal vasculature in cystathionine-&#946;-synthase heterozygous mice: a model of mild to moderate hyperhomocysteinemia</article-title><source>The American Journal of Pathology</source><volume>184</volume><fpage>2573</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.05.018</pub-id><pub-id pub-id-type="pmid">25016930</pub-id><pub-id pub-id-type="pmcid">PMC4188277</pub-id></element-citation></ref><ref id="ref-73"><label>Trudeau et&#160;al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trudeau</surname><given-names>K</given-names></name><name name-style="western"><surname>Molina</surname><given-names>AJA</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy</article-title><source>The American Journal of Pathology</source><volume>177</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.091029</pub-id><pub-id pub-id-type="pmid">20522647</pub-id><pub-id pub-id-type="pmcid">PMC2893686</pub-id></element-citation></ref><ref id="ref-74"><label>Tura et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tura</surname><given-names>A</given-names></name><name name-style="western"><surname>Herfs</surname><given-names>V</given-names></name><name name-style="western"><surname>Maa&#223;en</surname><given-names>T</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>H</given-names></name><name name-style="western"><surname>Vardanyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Prasuhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>M</given-names></name><name name-style="western"><surname>Kakkassery</surname><given-names>V</given-names></name><name name-style="western"><surname>Grisanti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Quercetin impairs the growth of uveal melanoma cells by interfering with glucose uptake and metabolism</article-title><source>International Journal of Molecular Sciences</source><volume>25</volume><fpage>4292</fpage><pub-id pub-id-type="doi">10.3390/ijms25084292</pub-id><pub-id pub-id-type="pmid">38673877</pub-id><pub-id pub-id-type="pmcid">PMC11049862</pub-id></element-citation></ref><ref id="ref-75"><label>Vardanyan et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vardanyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Brosig</surname><given-names>A</given-names></name><name name-style="western"><surname>Merz</surname><given-names>H</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>M</given-names></name><name name-style="western"><surname>Kakkassery</surname><given-names>V</given-names></name><name name-style="western"><surname>Grisanti</surname><given-names>S</given-names></name><name name-style="western"><surname>Tura</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metastasis of uveal melanoma with monosomy-3 is associated with a less glycogenetic gene expression profile and the dysregulation of glycogen storage</article-title><source>Cancer</source><volume>12</volume><fpage>2101</fpage><pub-id pub-id-type="doi">10.3390/cancers12082101</pub-id><pub-id pub-id-type="pmcid">PMC7463985</pub-id><pub-id pub-id-type="pmid">32751097</pub-id></element-citation></ref><ref id="ref-76"><label>Verbakel et&#160;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbakel</surname><given-names>SK</given-names></name><name name-style="western"><surname>Van Huet</surname><given-names>RAC</given-names></name><name name-style="western"><surname>Boon</surname><given-names>CJF</given-names></name><name name-style="western"><surname>Den&#160;den Hollander</surname><given-names>AI</given-names></name><name name-style="western"><surname>Collin</surname><given-names>RWJ</given-names></name><name name-style="western"><surname>Klaver</surname><given-names>CCW</given-names></name><name name-style="western"><surname>Hoyng</surname><given-names>CB</given-names></name><name name-style="western"><surname>Roepman</surname><given-names>R</given-names></name><name name-style="western"><surname>Klevering</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Non-syndromic retinitis pigmentosa</article-title><source>Progress in Retinal and Eye Research</source><volume>66</volume><fpage>157</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2018.03.005</pub-id><pub-id pub-id-type="pmid">29597005</pub-id></element-citation></ref><ref id="ref-77"><label>Vingolo et&#160;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vingolo</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mascolo</surname><given-names>S</given-names></name><name name-style="western"><surname>Miccich&#232;</surname><given-names>F</given-names></name><name name-style="western"><surname>Manco</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Retinitis pigmentosa: from pathomolecular mechanisms to therapeutic strategies</article-title><source>Medicina</source><volume>60</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.3390/medicina60010189</pub-id><pub-id pub-id-type="pmid">38276069</pub-id><pub-id pub-id-type="pmcid">PMC10819364</pub-id></element-citation></ref><ref id="ref-78"><label>Warburg (1956)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warburg</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1956">1956</year><article-title>On respiratory impairment in cancer cells</article-title><source>Science</source><volume>124</volume><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1126/science.124.3215.269</pub-id><pub-id pub-id-type="pmid">13351639</pub-id></element-citation></ref><ref id="ref-79"><label>Weh et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weh</surname><given-names>E</given-names></name><name name-style="western"><surname>Lutrzykowska</surname><given-names>Z</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Hager</surname><given-names>H</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>M</given-names></name><name name-style="western"><surname>Wubben</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Besirli</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hexokinase 2 is dispensable for photoreceptor development but is required for survival during aging and outer retinal stress</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><fpage>422</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2638-2</pub-id><pub-id pub-id-type="pmid">32499533</pub-id><pub-id pub-id-type="pmcid">PMC7272456</pub-id></element-citation></ref><ref id="ref-80"><label>Weidmann et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weidmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Pomerleau</surname><given-names>J</given-names></name><name name-style="western"><surname>Trudel-Vandal</surname><given-names>L</given-names></name><name name-style="western"><surname>Landreville</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential responses of choroidal melanocytes and uveal melanoma cells to low oxygen conditions</article-title><source>Molecular Vision</source><volume>23</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">28356703</pub-id><pub-id pub-id-type="pmcid">PMC5360455</pub-id></element-citation></ref><ref id="ref-81"><label>Wu et&#160;al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Justus</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T-T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C-S</given-names></name><name name-style="western"><surname>Bassuk</surname><given-names>AG</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>VB</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR repair reveals causative mutation in a preclinical model of retinitis pigmentosa</article-title><source>Molecular Therapy</source><volume>24</volume><fpage>1388</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.107</pub-id><pub-id pub-id-type="pmid">27203441</pub-id><pub-id pub-id-type="pmcid">PMC5023380</pub-id></element-citation></ref><ref id="ref-82"><label>Wubben et&#160;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wubben</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Toolan</surname><given-names>K</given-names></name><name name-style="western"><surname>Hager</surname><given-names>H</given-names></name><name name-style="western"><surname>Besirli</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Photoreceptor metabolic reprogramming provides survival advantage in acute stress while causing chronic degeneration</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>17863</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-18098-z</pub-id><pub-id pub-id-type="pmid">29259242</pub-id><pub-id pub-id-type="pmcid">PMC5736549</pub-id></element-citation></ref><ref id="ref-83"><label>Wubben et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wubben</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>M</given-names></name><name name-style="western"><surname>Weh</surname><given-names>E</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Sajjakulnukit</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Hager</surname><given-names>H</given-names></name><name name-style="western"><surname>Pai</surname><given-names>MP</given-names></name><name name-style="western"><surname>Lyssiotis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Besirli</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Small molecule activation of metabolic enzyme pyruvate kinase muscle isozyme 2, PKM2, circumvents photoreceptor apoptosis</article-title><source>Scientific Reports</source><volume>10</volume><issue>1</issue><fpage>2990</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-59999-w</pub-id><pub-id pub-id-type="pmid">32076076</pub-id><pub-id pub-id-type="pmcid">PMC7031539</pub-id></element-citation></ref><ref id="ref-84"><label>Xu, Zhao &amp; Kang (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The formation and renewal of photoreceptor outer segments</article-title><source>Cell</source><volume>13</volume><fpage>1357</fpage><pub-id pub-id-type="doi">10.3390/cells13161357</pub-id><pub-id pub-id-type="pmcid">PMC11352558</pub-id><pub-id pub-id-type="pmid">39195247</pub-id></element-citation></ref><ref id="ref-85"><label>Yao et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma</article-title><source>Autophagy</source><volume>18</volume><fpage>1879</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.2007027</pub-id><pub-id pub-id-type="pmid">34890308</pub-id><pub-id pub-id-type="pmcid">PMC9450969</pub-id></element-citation></ref><ref id="ref-86"><label>You et&#160;al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>I-C</given-names></name><name name-style="western"><surname>Coursey</surname><given-names>TG</given-names></name><name name-style="western"><surname>Bian</surname><given-names>F</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>FL</given-names></name><name name-style="western"><surname>De Paiva</surname><given-names>CS</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Macrophage phenotype in the ocular surface of experimental murine dry eye disease</article-title><source>Archivum Immunologiae Et Therapiae Experimentalis</source><volume>63</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/s00005-015-0335-0</pub-id><pub-id pub-id-type="pmid">25772203</pub-id><pub-id pub-id-type="pmcid">PMC4523394</pub-id></element-citation></ref><ref id="ref-87"><label>Yumnamcha et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yumnamcha</surname><given-names>T</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>LP</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metabolic dysregulation and neurovascular dysfunction in diabetic retinopathy</article-title><source>Antioxidants</source><volume>9</volume><fpage>1244</fpage><pub-id pub-id-type="doi">10.3390/antiox9121244</pub-id><pub-id pub-id-type="pmid">33302369</pub-id><pub-id pub-id-type="pmcid">PMC7762582</pub-id></element-citation></ref><ref id="ref-88"><label>Zhang et&#160;al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Justus</surname><given-names>S</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C-W</given-names></name><name name-style="western"><surname>Bonet-Ponce</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W-P</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duong</surname><given-names>JK</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>VB</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C-S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>JB</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>4659</fpage><lpage>4673</lpage><pub-id pub-id-type="doi">10.1172/JCI86905</pub-id><pub-id pub-id-type="pmid">27841758</pub-id><pub-id pub-id-type="pmcid">PMC5127684</pub-id></element-citation></ref><ref id="ref-89"><label>Zhang et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>E</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J</given-names></name><name name-style="western"><surname>Levi</surname><given-names>SR</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JK</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CW</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T-T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N-K</given-names></name><name name-style="western"><surname>Limade&#160;Carvalho</surname><given-names>JR</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PKM2 ablation enhanced retinal function and survival in a preclinical model of retinitis pigmentosa</article-title><source>Mammalian Genome</source><volume>31</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s00335-020-09837-1</pub-id><pub-id pub-id-type="pmid">32342224</pub-id><pub-id pub-id-type="pmcid">PMC9578386</pub-id></element-citation></ref><ref id="ref-90"><label>Zhang et&#160;al. (2025)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Subretinal fibrosis secondary to neovascular age-related macular degeneration: mechanisms and potential therapeutic targets</article-title><source>Neural Regeneration Research</source><volume>20</volume><fpage>378</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.4103/NRR.NRR-D-23-01642</pub-id><pub-id pub-id-type="pmid">38819041</pub-id><pub-id pub-id-type="pmcid">PMC11317958</pub-id></element-citation></ref><ref id="ref-91"><label>Zhao et&#160;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A multi-omics deep learning model for hypoxia phenotype to predict tumor aggressiveness and prognosis in uveal melanoma for rationalized hypoxia-targeted therapy</article-title><source>Computational and Structural Biotechnology Journal</source><volume>20</volume><fpage>3182</fpage><lpage>3194</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2022.06.034</pub-id><pub-id pub-id-type="pmid">35782742</pub-id><pub-id pub-id-type="pmcid">PMC9232399</pub-id></element-citation></ref><ref id="ref-92"><label>Zhou et&#160;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Geathers</surname><given-names>JS</given-names></name><name name-style="western"><surname>Grillo</surname><given-names>SL</given-names></name><name name-style="western"><surname>Weber</surname><given-names>SR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sundstrom</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of epithelial-mesenchymal transition in retinal pigment epithelium dysfunction</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>8</volume><fpage>501</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.00501</pub-id><pub-id pub-id-type="pmid">32671066</pub-id><pub-id pub-id-type="pmcid">PMC7329994</pub-id></element-citation></ref><ref id="ref-93"><label>Zhu et&#160;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PKM2 is a potential diagnostic and therapeutic target for retinitis pigmentosa</article-title><source>Disease Markers</source><volume>2021</volume><elocation-id>1602797</elocation-id><pub-id pub-id-type="doi">10.1155/2021/1602797</pub-id><pub-id pub-id-type="pmid">34804260</pub-id><pub-id pub-id-type="pmcid">PMC8601838</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>